medical research companies in nj

• Diversity in Clinical Research
• Clinical Research for Older Populations
• Clinical Research for Compensation
• Clinical Trial Information for Parents
• What Is A Clinical Trial?

New Jersey Paid Clinical Trials

Match to clinical trials, popular cities, search clinical trials in new jersey by condition.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. Policylab.us does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. All viewers of this content, especially those taking prescription or over-the-counter medications, should consult their physicians before beginning any nutrition, supplement or lifestyle program

Biotech in New Jersey: Nine companies leading the charge

New Jersey’s biotech sector is recognized as a major hub of innovation and industry in the pharmaceutical and biotechnological landscapes. According to Genetic Engineering and Biotechnology News ’ 2023 ranking, New Jersey is the 4th most important biotech hub in the U.S. with innovative biotech companies in its ecosystem.

With $2.49 billion in venture capital investment in 2022 and the first half of 2023 and over 140,000 biotech jobs in the region, New Jersey is home to industry leaders such as Johnson & Johnson or Bristol Myers Squibb. But industry giants aren’t the only ones to call New Jersey home. Here are nine biotech companies to put on your radar.

Table of contents

Bioaegis therapeutics.

BioAegis Therapeutics, based in North Brunswick, New Jersey, is a clinical-stage biotech company that focuses on developing therapies based on plasma gelsolin, a naturally occurring human protein known for its role in modulating inflammation and immune response. The company aims to harness plasma gelsolin to treat a variety of conditions where inflammation plays a critical role.

BioAegis’ flagship project involves the development of recombinant human plasma gelsolin (rhu-pGSN) for the treatment of acute and chronic inflammatory diseases, including acute respiratory distress syndrome (ARDS). ARDS is a severe lung condition often seen in critically ill patients, and it represents a significant area of unmet medical need. The company’s approach leverages plasma gelsolin’s ability to modulate the body’s immune response without causing immunosuppression, offering potential treatments for diseases driven by inflammation and infection.

The company has received $20 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance its gelsolin therapy. It has also received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for its inflammation regulator protein, allowing it to proceed with clinical trials designed to evaluate the efficacy and safety of its therapy.

Based in Florham Park, New Jersey, Celularity develops cellular therapies derived from the human placenta. These therapies are aimed at treating a variety of diseases, including cancer, immune disorders, and other conditions.

Celularity’s pipeline features several promising products, including CYCART-19 for lymphoma, and CYNK-301 for acute myeloid leukemia. It is also developing therapies for non-small cell lung cancer and osteoarthritis. The company’s therapies utilize a range of cellular technologies, including CAR-T and NK cell therapies, to target diseases at the cellular level.

Suggested Articles

Five biotech companies taking florida by storm, 5 advancements in rare disease research over the past year, 6 biotechnology universities in the us nurturing tomorrow’s trailblazers, six companies that have made their name in the cardiovascular space, six nanotechnology companies to watch out for.

The New Jersey Biotech company has partnerships in place with major pharmaceutical players like Sorrento Therapeutics and more recently Regeneron Pharmaceuticals . Additionally, Celularity received regulatory advancements, such as the Healthcare Common Procedure Coding System (HCPCS) Q Code for one of their biomaterial products, Biovance, facilitating health insurance claims by Medicare and thus its use in clinical settings.

EpiBone was founded in 2013, and is soon relocating from Brooklyn to Jersey City, New Jersey. The company is at the forefront of regenerative medicine, focusing on skeletal reconstruction by utilizing stem cell technology and engineering principles to grow bone and cartilage tailored to individual needs.

EpiBone’s core technology leverages the patient’s stem cells to grow bone and cartilage in the lab. This process begins with a CT scan of the patient’s bone defect, which is used to create a precise digital model. Stem cells harvested from the patient’s fat tissue are then cultured and grown on a scaffold in a bioreactor that mimics the body’s natural conditions. This innovative approach allows the engineered bone to integrate seamlessly with the patient’s body, potentially reducing the risks associated with immune rejection and improving recovery times.

EpiBone has raised a total of $33.8 million across multiple funding rounds and has also been supported by a $3.5 million Emerge tax credit from the New Jersey Economic Development Authority, aiding its relocation and expansion​. EpiBone is currently involved in clinical trials, including a significant study on knee cartilage replacement, which has received ND clearance from the FDA.

Iveric Bio, part of Astellas Pharma, is focusing on the development of novel treatments for retinal diseases, including age-related macular degeneration (AMD).

Iveric Bio’s main product in development is Zimura (avacincaptad pegol), a complement C5 inhibitor, which plays a role in inflammation and cell destruction, aimed at treating geographic atrophy (GA), an advanced form of AMD that lacks FDA-approved treatment options.  Specifically, Zimura is designed to inhibit the activity of complement C5, thereby preventing the formation of a group of proteins known as the membrane attack complex (MAC) that can damage cells and tissues.  Zimura has demonstrated promising results in phase 3 clinical trials GATHER1 and GATHER2, showing potential to slow the progression of GA by targeting the complement pathway, a key factor in the disease’s development.

Iveric Bio has recently been granted approval by the FDA for Zimura, a significant milestone for the company but also for patients as it is the first FDA-approved treatment for GA.

Kayothera develops precision medicines for oncology. The biotech company, established in 2019, is based in Princeton, New Jersey, and focuses on small-molecule drugs that target the retinoid signaling pathway. Retinoids are chemical compounds that are derivatives of vitamin A. This pathway is essential for a variety of biological processes including cell differentiation, cell growth, programmed cell death, and the maintenance of the proper function of the immune system.

Kayothera’s primary therapeutic candidates include KAYO-1609 and other small-molecule inhibitors. KAYO-1609, its lead compound, is designed to inhibit the heat shock factor 1 (HSF1) pathway, which is crucial for the survival and proliferation of cancer cells. This drug is being developed as a potential treatment for various solid tumors, including ovarian carcinoma and other cancers. Kayothera expects to file an FDA IND application by the end of 2024.

Kayothera has recently completed a notable extended series A financing round, raising $14 million to support the advancement of its lead candidate into clinical development.

Nuvectis Pharma

Nuvectis Pharma is a biopharmaceutical company based in Fort Lee, New Jersey, focusing on the development of precision medicines in oncology. The company was established in 2020, and aims to innovate in the treatment of cancer with targeted therapeutics.

Nuvectis Pharma is developing novel small-molecule drugs, including NXP800 and NXP900, which are designed to target specific pathways involved in cancer progression. NXP800 is an oral inhibitor of the heat shock factor 1 (HSF1) pathway, currently in phase 1b clinical trials for the treatment of patients with ARID1a-mutated ovarian carcinoma, a condition with few effective treatments. In cancer, the HSF1 pathway is often upregulated, leading to increased expression of HSPs that can protect cancer cells from stressful conditions within tumors, such as hypoxia and nutrient deprivation. By aiding in the survival of these malignant cells, HSF1 contributes to tumor progression and resistance to therapies. 

NXP900 targets the proto-oncogene c-Src and YES1 kinases, with phase 1a trials underway. c-Src is implicated in numerous cancer-related pathways. It plays a significant role in promoting cancer cell growth, survival, invasion, and metastasis. Over-activation of c-Src has been observed in various cancers, such as colon, liver, lung, breast, and pancreatic cancers, and is often associated with poor clinical prognosis. Similar to c-Src, YES1 is involved in cell growth and survival, and its dysregulation has been linked to the development and progression of cancer. YES1 has been identified as a critical mediator in signaling pathways that contribute to the malignant behavior of cancer cells, including aiding in the evasion of immune surveillance. By targeting both c-Src and YES1 kinases, NXP900 aims to inhibit these critical pathways, potentially leading to reduced tumor growth, decreased metastasis, and improved responses to existing cancer therapies.

In 2021, Nuvectis Pharma raised $15 million through a series A funding and licensed the rights to develop and commercialize NXP800. 

PDS Biotechnology

PDS Biotechnology is a clinical-stage biotech company based in Princeton, New Jersey. It was founded in 2005 with the objective to develop targeted immunotherapies for cancer and infectious diseases using its proprietary Versamune platform. This platform is designed to enhance the body’s immune response against diseases by activating T cells in a way that improves treatment efficacy with manageable toxicity profiles.

Its lead product, PDS0101, targets human papillomavirus (HPV)-associated cancers by combining the Versamune platform with other immunotherapies to enhance disease control and survival rates. The key mechanism of PDS0101 involves the presentation of HPV-specific antigens to the immune system, enabling the activation of T-cells that can identify and destroy cancer cells expressing these antigens. The company also has other candidates like PDS0301, an interleukin-12 based therapy, and PDS0202, a novel influenza vaccine, under development.

PDS Biotechnology has reported promising results from phase 2 clinical trials involving PDS0101 for treating HPV-positive head and neck cancers, showing significant survival benefits and clinical responses. Additionally, the company has collaborated with notable institutions such as the National Cancer Institute (NCI).

Rocket Pharmaceuticals

Rocket Pharmaceuticals , headquartered in Cranbury, New Jersey, is focused on developing gene therapies for rare genetic disorders. The company is utilizing both adeno-associated viruses (AAV), small viruses that can deliver genetic material into cells without causing disease, and lentiviral vector (LVV) technologies, derived from the human immunodeficiency virus (HIV), with the ability to integrate into the host cell genome, to create treatments for diseases that have historically had limited treatment options.

Rocket’s therapeutic pipeline includes projects targeting Fanconi anemia (FA), leukocyte adhesion deficiency type I (LAD-I), and Danon disease.

Rocket Pharmaceuticals has recently made significant strides in advancing its clinical programs. Notably, the company’s therapy for LAD-I, referred to as RP-L201, has been recognized with various FDA designations such as Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric Disease, and Orphan Drug designations, which could facilitate a faster review process by the FDA. It is currently in a phase 1/2 clinical trial. 

Additionally, the company’s treatment for Danon disease, RP-A501 , is notable as it represents one of the first potential gene therapy approaches for this condition, having also received RMAT designation from the FDA and is currently in phase 2 clinical trials.

Timber Pharmaceuticals

Timber Pharmaceuticals, located in Basking Ridge, New Jersey, concentrates on developing treatments for rare and orphan dermatological diseases.

Timber Pharmaceuticals’ pipeline includes several promising candidates, such as TMB-001, a topical formulation of isotretinoin intended for the treatment of congenital ichthyosis (CI), a group of rare genetic skin disorders characterized by dry, thickened, and scaling skin. Isotretinoin, traditionally used in oral form for severe acne, works by reducing the production of sebum and altering the lifecycle of skin cells. The topical application as seen in TMB-001 aims to concentrate its effects on the skin, potentially reducing systemic side effects and focusing the treatment on the areas most affected by the disease. TMB-001 has received Breakthrough Therapy and Fast Track designations from the FDA and is currently in phase 3.

The company also develops TMB-003, for sclerotic skin diseases. By focusing on the underlying mechanisms of skin fibrosis and sclerosis, TMB-003 seeks to reduce the progression of skin thickening and improve symptoms associated with the disease. 

In August 2023, LEO Pharma signed an agreement to acquire Timber Pharmaceuticals. This acquisition is intended to enhance LEO Pharma’s pipeline in medical dermatology by adding TMB-001, the main asset of the company to its portfolio.

New Jersey: A critical biotech hub in the US

New Jersey is poised to remain a critical hub for biotech innovation due to its dense concentration of pharmaceutical and biotech companies. This environment fosters collaboration and the rapid development of new technologies and therapies. The state government continues to support the biotech industry through incentives such as tax breaks, funding opportunities, and support services for startups. This support helps to maintain a fertile environment for new and existing companies to grow and thrive.

New Jersey’s strong ties with academic institutions and research facilities contribute to its leading role in biotech research and development. These relationships not only help in the advancement of scientific research but also in the commercialization of new discoveries. The availability of a highly skilled workforce is another key driver. With several top universities and research institutions, New Jersey can provide the biotech industry with skilled professionals.

Partnering 2030: The Biotech Perspective 2023

Latest Articles

The future of combination vaccines, eight biotech companies you should know about in spain, glp-1 shortage: can biotech companies keep up with rising demand, could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential.

Top 23 Medical Device Innovators in New Jersey

The medical device industry in New Jersey houses a rich collection of companies that specialize in providing high-quality healthcare solutions. These companies design, manufacture, and supply a broad spectrum of innovative devices for diagnosis, treatment, and prevention. The products of this industry span across various medical fields such as orthopedics, vascular access management, stroke care, surgical specialties, and more. With the increasing demand for precision medicine and personalized healthcare, these companies play a pivotal role in advancing the medical sector. In addition, they continually invest in research and development, hinting at the future growth and innovation potential of the industry.

Top 23 medical devices companies in New Jersey

• Website: bd.com
• Headquarters: Franklin Lakes, New Jersey, United States
• Founded: 2009
• Headcount: 10001+
• Latest funding type: Grant

BD is a leading global medical technology company that offers a wide range of instruments, assays, and reagents used in hospitals and labs. They provide solutions for diagnostic accuracy, patient safety, surgical procedures, infectious disease testing, and vascular access management.

2. Johnson & Johnson Medical Devices Companies

• Website: jnjmedicaldevices.com
• Headquarters: New Brunswick, New Jersey, United States
• Founded: 1886
• Latest funding type: Acquired

JNJ Medical Devices offers a range of innovative medical solutions in the healthcare industry, focusing on improving patient outcomes and quality of life. Their advanced technology and expertise cater to various medical needs, including surgical specialties, orthopedics, cardiovascular, and more.

3. Johnson & Johnson MedTech

• Website: jnjmedtech.com

J&J MedTech is a medical technology company that offers a range of products and solutions for stroke care, including hemorrhagic and ischemic stroke. They provide medical devices and services to support healthcare professionals, patients, and caregivers. With a focus on customer service and a commitment to improving patient outcomes, J&J MedTech aims to be a trusted partner in stroke care.

4. Mindray North America

• Website: mindraynorthamerica.com
• Headquarters: Mahwah Township, New Jersey, United States
• Founded: 1991
• Headcount: 5001-10000

Mindray North America offers a comprehensive range of patient monitoring, anesthesia, and ultrasound imaging devices and systems. They provide wearable patient monitors, clinical workflow solutions, and high-quality medical equipment to enhance patient care.

5. Integra LifeSciences

• Website: integralife.com
• Headquarters: Princeton, New Jersey, United States
• Founded: 1989
• Headcount: 1001-5000
• Latest funding type: Post Ipo Equity

Integra Life Sciences is a company dedicated to improving healthcare outcomes through innovative medical solutions. With a focus on research and development, they provide artificial skin, surgical tools, and medical devices that help patients heal faster and surgeons perform complex operations. They offer a range of career opportunities for individuals who want to make a difference in the field of healthcare.

• Website: hiossen.com
• Headquarters: Englewood Cliffs, New Jersey, United States
• Founded: 2006
• Headcount: 201-500

HiOssen is a company that offers a wide range of dental implant products and services. They provide products like twist drills, abutments, biomaterials, surgical instruments, and more. Their offerings cater to dentists and dental clinics looking for high-quality and reliable dental implant solutions.

7. Canfield Scientific

• Website: canfieldsci.com
• Headquarters: Parsippany, New Jersey, United States
• Founded: 1988
• Headcount: 51-200

Canfield Scientific, Inc. is a leading developer of specialized photographic systems and imaging software for medical practices, institutions, research organizations, and pharmaceutical suppliers. They offer high-quality, standardized facial imaging solutions that include 3D visual tools, side-by-side comparisons, and quantitative analysis. Canfield's technology helps healthcare professionals capture accurate and detailed images, enabling them to provide the highest standard of care to their patients.

8. Case Medical, Inc.

• Website: casemed.com
• Headquarters: Bloomfield, New Jersey, United States
• Founded: 1992

Case Medical is a U.S manufacturer of medical instrument processing solutions that enable healthcare facilities to improve quality of care, patient outcomes, and reduce costs.

• Website: katena.com
• Founded: 1975

Katena is a company that specializes in high-quality ophthalmic devices and surgical products. They offer a wide range of products including single-use instruments, biologics, lenses, and plugs. Their mission is to be the global leader in ophthalmic devices, providing clinicians with essential tools for sight restoration.

10. Medin Corporation

• Website: medin.com
• Headquarters: Totowa, New Jersey, United States
• Founded: 1966

Medin is a company that offers practical medical device solutions, resolving pain points promptly and efficiently. With a state-of-the-art lean manufacturing facility and continuous investment in new technologies, they deliver what customers need quickly and cost-effectively.

11. Alfa Wassermann Diagnostic Technologies

• Website: alfawassermannus.com
• Headquarters: West Caldwell, New Jersey, United States
• Founded: 1960

Alfa Wassermann is a company that specializes in serving physician office laboratories and hospitals. They offer chemistry analyzers, middleware solutions, and provide tools, technology, and training for healthcare laboratories. With a focus on lipid management, Alfa Wassermann highlights the role of HDL-C in improving patient outcomes.

12. Capintec, Inc.

• Website: capintec.com
• Headquarters: Florham Park, New Jersey, United States
• Founded: 1965

Capintec is a company that specializes in providing standard or custom-configured nuclear medicine equipment and accessories. They offer a wide range of products including dose calibrators, thyroid uptake systems, well counters, radiation monitoring equipment, and more.

13. Cygnus Medical

• Website: cygnusmedical.com
• Headquarters: Fairfield, New Jersey, United States
• Headcount: 11-50

Cygnus Medical specializes in providing innovative solutions for drying coiled scopes and instrument channels. Their Airtime™ products, such as the Variable Flow Rate Unit (VFR100) and External Air Supply Unit (ATEAS01), offer efficient and controlled airflow to prevent overpressurization and minimize drying times. With a focus on maintaining instrument quality and reducing moisture-related risks, Cygnus Medical is a trusted partner for healthcare facilities.

14. Rayence Inc.

• Website: rayenceusa.com
• Headquarters: Closter, New Jersey, United States
• Founded: 2010

Rayence is a company specializing in digital X-ray imaging solutions. They offer low dose digital X-ray imaging technology for a variety of medical fields including orthopedics, chiropractic, podiatry, and urgent care. Their solutions are used in hospitals, imaging centers, and mobile units, providing improved sensitivity at lower doses. Rayence is dedicated to providing innovative technology to improve medical imaging capabilities.

15. gSource

• Website: gsource.com
• Headquarters: Emerson, New Jersey, United States
• Founded: 1999

gSource, LLC is a company that specializes in providing high-quality surgical instruments. They offer a wide range of instruments for medical professionals, including burs, retractors, grasper retractors, and more. With their German craftsmanship and precision machining, they ensure the finest quality instruments for surgeons worldwide.

16. BihlerMED

• Website: bihlermed.com
• Headquarters: Phillipsburg, New Jersey, United States

BihlerMed is a medical equipment manufacturer that specializes in developing ergonomic surgical lighting systems. They offer handheld, battery-powered, and cable-free lights with several different illumination options that can be attached to surgical tools.

17. Physitemp Instruments, LLC

• Website: physitemp.com
• Headquarters: Clifton, New Jersey, United States

Physitemp designs and manufactures precision temperature sensors for the medical device industry. With 45 years of expertise, the company offers Type T thermocouple microprobes and temperature controllers with high accuracy and traceability to NIST standards.

18. Corza Ophthalmology

• Website: corzaeye.com

Corza Ophthalmology offers high-quality ophthalmic devices and surgical products essential to clinicians at every step along the patient’s sight restoration pathway. Their products include ambio allografts, Sharpoint stab knives, and hands-free gonio lens.

19. Home Medical Equipment Classifieds

• Website: home-medical-equipment-classifieds.com
• Headquarters: Eatontown, New Jersey, United States
• Headcount: 1-10

Buy, sell, and trade medical equipment and medical supplies with free photo classified ads. Put your good used medical equipment back in use for others to buy and enjoy. Visit our extensive medical equipment directory.

20. BioSenseTek

• Website: biosensetek.com
• Headquarters: Morristown, New Jersey, United States
• Founded: 2003

BioSenseTek is a leading-edge research and design company specializing in the development of bioelectrical/physiological sensors and signal processing instruments.

21. Amromed LLC

• Website: amromed.com
• Headquarters: Jersey City, New Jersey, United States
• Founded: 2012

Amromed is a company that offers various products and services.

22. Med Repair Tech

• Website: medrepairtech.com
• Headquarters: Morganville, New Jersey, United States
• Founded: 2013

Med Repair Tech is a company providing medical equipment and staffing solutions to all health sector facilities. Specializing in Repair, Maintenance, and Verification of medical devices to improve the reliability and performance of your biomedical machines today.

23. State of the Art Medical, Inc

• Website: sotamedical.com
• Headquarters: Cedar Grove, New Jersey, United States
• Founded: 1982

SOTA Medical is a company specializing in state-of-the-art medical products. They offer innovative and advanced solutions for the healthcare industry.

Want to find more medical devices companies?

If you want to find more companies that offer a wide spectrum of healthcare solutions you can do so with Inven . This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

• Ownership: Which of these are private equity backed? Which are family-owned?
• Contact data: Who are the owners and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!

Find companies 10x faster with Inven

Keep on reading

More articles.

The Top 6 Pharmaceutical Companies in New Jersey

Here are the top six pharmaceutical companies in New Jersey that have job openings now. Find out more about them before applying for a job.

New Jersey is one of the most important states in the U.S. pharmaceutical industry. The state is home to 14 of the 20 largest pharmaceutical companies in the U.S., and the New Jersey pharmaceutical industry generates over $120.9 billion in revenue each year , with 63,415 jobs directly linked to the industry.

Although the state of New Jersey is relatively small, it plays a large role in both the U.S. pharmaceutical industry and the Pharm Country hotbed. New Jersey is also number one in the country for heart medication and number two for cancer medication .

1. Johnson & Johnson

Johnson & Johnson has remained in the top spot on this list for many years. The company is headquartered in New Brunswick, NJ and employs over 140,000 people worldwide . J&J’s products include over-the-counter medications, medical devices and consumer products such as baby shampoo and Band-Aids.

On Sep. 22, the company opened up an R&D campus in San Francisco , which will focus on digital health and house around 400 employees. J&J has also been working on an immunotherapy treatment for cancer, which has achieved FDA approval this year .

Johnson & Johnson always has positions available for those with the right skills and qualifications. The company is currently looking for a senior IT lead product analyst, an associate director of regulatory affairs, and an AITA data and insights innovation director.

Although its home base is in New York City, Pfizer is one of the largest pharmaceutical companies in New Jersey. The company has over 4,000 employees in the state and is ranked 43rd on the Fortune 500 list.

Pfizer was founded in 1849 and today produces a wide range of prescription and over-the-counter medications. The company’s products include treatments for conditions such as Alzheimer’s disease, cancer, heart disease and arthritis. Most notably, the company was at the forefront of COVID-19 vaccine development, with its vaccine being one of the first to receive emergency use authorization from the FDA.

Pfizer is always looking for talented individuals to join its team. The company is currently hiring for a number of positions in New Jersey with remote work positions open for oncology field medical directors and associate directors for clinical pharma services.

Kenilworth, NJ is home to Merck , one of the oldest pharmaceutical companies in the United States. The company was founded in 1891 and employs close to 70,000 people worldwide.

Merck & Co. produces a wide range of prescription medications, vaccines, and animal health products. The company is currently working on Islatravir, a new treatment for HIV, which is expected to move to Phase III clinical trials on Tuesday.

Currently, the company is hiring for a number of positions in New Jersey, including analytical R&D scientists, senior research scientists and quality assurance specialists.

4. Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel. The company specializes in the research, development, and manufacturing of medications for a variety of conditions including Alzheimer’s disease, Parkinson’s disease, heart failure and more.

The company is relatively new, having been founded in 1996. However, it has quickly grown to employ over 108,000 people in 140 countries and now has several locations in New Jersey, including in East Hanover and Florham Park.

On Thursday, the company announced its plans to become a top five global pharmaceutical company by 2027. In order to achieve this goal, Novartis plans to focus on five core therapeutic areas.

Novartis has open positions available to senior analytical scientists, data scientists and associate global marketing managers.

Bayer is a German multinational pharmaceutical and life science company headquartered in Leverkusen. Bayer is perhaps best known for its wide range of over-the-counter medications, such as aspirin and Alka-Seltzer, however, the company has acquired a bit of a green thumb.

In 2018, Bayer acquired Monsanto in a $63 billion deal which made the company one of the leading players in the agrichemicals industry. The acquisition has allowed Bayer to develop new sustainable agriculture solutions to help farmers reduce their carbon footprint and increase their yields. The company also recently announced a collaboration with Perdue AgriBusiness to reduce carbon emissions and increase sustainability in the food value chain.

Bayer is currently hiring for a number of positions in New Jersey, including supply chain system managers and regulatory affairs managers.

6. Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in New York City. The company produces a wide range of prescription medications, including treatments for cancer, HIV/AIDS, diabetes, and heart disease.

The company has recently made headlines for its work on Opdualag (nivolumab and relatlimab), a new treatment for melanoma that was recently approved by the European Commission.

BMS also recently received approval for Sotyktu (deucravacitinib) for plaque psoriasis. This oral treatment is the first of its kind in almost a decade and avoids the need for a black box label, which is often required for injectable treatments for psoriasis.

At the moment, the company is looking for manufacturing associates, registered clinical scientists and pharmaceutical development technicians to join its team in New Jersey.

• Promoted Listings
• Purchase Data
• Drug Pipelines
• Data Licensing

New Jersey Biotech, Pharmaceutical & Life Sciences Companies

Paid Clinical Trials in New Jersey

Find paid studies that are recruiting healthy participants in New-Jersey-Paid-Studies. Filter by distance, duration, and inclusion criteria to find clinical trials that pay well for your time.

Popular Trials

Michael Bask Gill, B Sc

Last Reviewed: July 14th, 2024

Corticosteroid

Cortisone injections for trigger finger, this trial will compare one cortisone injection to two injections for the treatment of trigger finger..

Biomarker Analysis for Cervical Cancer Diagnosis

This trialstudies biomarkers to better diagnose cervical lesions, improving treatment plans for abnormal cervical cells..

Growth Hormone

Weekly growth hormone for growth hormone deficiency in children, this trial is testing altu-238, a medication for children who can't produce enough growth hormone. it aims to help these children grow and develop by providing the hormone they lack. the study will also check if a regular dose is effective. somatrogon is a long-acting recombinant human growth hormone being developed as a regular treatment for children with growth hormone deficiency (ghd)..

Behavioural Intervention

Robotic arm therapy for stroke, this trial will test whether adding robotic therapy to standard occupational therapy can help stroke patients recover arm movement faster and more accurately..

Tyrosine Kinase Inhibitor

Cabozantinib for non-small cell lung cancer, this trial will help us understand if cabozantinib can help patients with gene ret, ros1, or ntrk fusion or increased met or axl activity by inhibiting these genes that lead to lung cancer cell growth..

Proton Therapy vs. IMRT for Prostate Cancer

This trial is studying whether men being treated for prostate cancer have the same amount of side effects from either one of two different external radiation treatments: imrt or pbt., popular filters, phase 3 trials.

Alkylating agents

Combination chemotherapy for ewing's sarcoma, this trial is studying different combination chemotherapy regimens to see how well they work when given with or without peripheral stem cell transplantation, radiation therapy, and/or surgery in treating patients with ewing's sarcoma..

Platinum-based Chemotherapy

Chemo-radiation for early-stage cervical cancer, this trial is studying how well giving chemotherapy and pelvic radiation therapy together with or without additional chemotherapy works in treating patients with high-risk early-stage cervical cancer..

Hormone Therapy

Mf101 for hot flashes, this trial tests mf101, a plant-based treatment, on postmenopausal women aged 40-65 with moderate to severe hot flushes. it aims to reduce hot flushes using natural ingredients without hormones. the study will compare its safety and effectiveness over a few months. mf101 has been previously shown to be safe and effective in reducing hot flashes in postmenopausal women., radiation and temozolomide vs. pcv chemotherapy for brain tumor, this trial is testing whether giving radiation therapy with temozolomide drugs is more effective in treating brain tumors than giving radiation with another type of drug., behavioral intervention, lifestyle changes for ovarian cancer, this trial is testing whether changes in diet and physical activity can help patients with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer returning..

Janus Kinase (JAK) Inhibitor

Tofacitinib for juvenile arthritis, this trial will evaluate the long-term safety and tolerability of tofacitinib in patients with juvenile idiopathic arthritis (jia) who have previously participated in tofacitinib jia studies., trials with no placebo.

Surgery + Chemotherapy + IMRT for Mesothelioma

This trial is testing a new, safer radiation therapy for people with a certain type of lung cancer. the old radiation therapy had lots of side effects, but the new one specifically targets the cancer and reduces the risk of damaging healthy tissue..

FDG and DHT PET Imaging for Prostate Cancer

This trial will use pet scans with a radiotracer to see if it can more accurately find where prostate cancer has spread in the body..

CA 125 Blood Test for Early Detection of Ovarian Cancer

This trial is testing whether a blood test can detect ovarian cancer early in women who are at low risk., chemotherapy, personalized adaptive novel agents for breast cancer, this trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. it focuses on identifying which treatments work best based on specific cancer characteristics. early signs of success are monitored using mri scans and tests on blood and tissue samples., view more related trials.

Total Hip Arthoplasty

ProstAtak® Immunotherapy

Lymph node template

Eflornithine +1 More

[18F]-ML-10 in conjunction with PET imaging

Varenicline

Cisplatin +2 More

Pomalidomide +2 More

Axillary Lymph Node Dissection (ALND) +1 More

Guided Imagery +1 More

Observation

Cytoreductive Surgery

Cetuximab +3 More

Cyclosporins +4 More

Therapeutic Conventional Surgery

Cisplatin +4 More

Electronic Skin Surface Brachytherapy

Whole Body Vibration

Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments

Intensive Medical Management - no CEA +3 More

Portico Re-sheathable Transcatheter Aortic Valve System

Proton Beam Radiation Therapy +1 More

Blastocyst Biopsy with Whole Chromosome Analysis

Pegylated Liposomal Doxorubicin Hydrochloride +1 More

Nivolumab +1 More

multi-parametric MRI(MP-MRI)

Odronextamab

Dabrafenib Mesylate +1 More

Prednisone +4 More

Biospecimen Collection

Temozolomide +2 More

Carboplatin +4 More

Hyperpolarized Pyruvate

iCasp9M28z T cell infusions

IORT with CT-Guided HDR Brachytherapy

Levonorgestrel-Releasing Intrauterine System

Surgery +2 More

Selinexor +9 More

Ipilimumab +1 More

Isatuximab +1 More

BTCT4465A (Mosunetuzumab) +1 More

Pathologic evaluation of excised tissue

GORE® EXCLUDER® Conformable AAA Endoprosthesis

Doxorubicin Hydrochloride +2 More

SAbR +1 More

Capivasertib +18 More

Cisplatin +1 More

Symplicity Spyral™ multi-electrode renal denervation system

CardiAMP™ Cell Therapy

Melphalan +4 More

Cyclophosphamide +4 More

Berzosertib (M6620) +2 More

DFMO +4 More

coflex® Interlaminar Technology +1 More

Perfusion Magnetic Resonance Imaging

GSK2256098 +3 More

Triathlon Tritanium Cone Augments

Corneal tissue inlay

VIP152 (BAY 1251152)

Whole-Brain Radiation Therapy

Vodobatinib (K0706)

Lenalidomide +4 More

Pembrolizumab

somapacitan

Proton +1 More

View more Paid Studies New Jersey

See more medical studies focusing on Paid Studies New Jersey

Frequently Asked Questions

Other Trials to Consider

Part 2: ASP1012 + Pembrolizumab Dose Expansion (previously treated solid tumors)

Dose escalation and expansion xmab662 administered as monotherapy, io102/io103, nivolumab, and relatlimab, io102-io103, popular categories.

Clinical Trials in New York

Clinical Trials in Oklahoma

Clinical Trials in Mississippi

Paid Clinical Trials in Albuquerque, NM

Paid Clinical Trials in Knoxville, TN

Paid Clinical Trials in New York City, NY

Paid Clinical Trials in New York

Paid Clinical Trials in Pennsylvania

Paid Clinical Trials in Michigan

Paid Clinical Trials in Maine

Paid Clinical Trials in Kentucky

Paid Clinical Trials in Connecticut

Paid Clinical Trials in Arizona

Paid Clinical Trials in New Mexico

Paid Clinical Trials in Wyoming

Popular guides.

Content types

• Infographics
• Case studies
• Press releases
• Career Advice
• Contracting/Freelancing
• Digital health
• Employee Engagement & Retention
• Employer Advice
• Employer Brand
• Life Science news
• Proclinical News
• Working in Recruitment
• Workplace Diversity

Latest jobs

Highly Competitive

Galway, Republic of Ireland

Proclinical is currently recruiting for an R-D Engineer I to join a dedicated team. This is a temporary contract position based in Galway, Ireland.

Gaithersburg, USA

Proclinical is seeking a dedicated Quality Control Scientist with a strong analytical and compliance background with proven troubleshooting and investigational skills.

Top 10 biggest life science employers in New Jersey

Hailed as a life science hub, New Jersey is the home to an impressive collection of pharmaceutical, biotechnology and medical device companies, many of which are industry leaders. In 2015, 50% of new FDA approvals came from companies that have a base in the New Jersey region. Employing approximately 116,000 people, New Jersey is a thriving nucleus of life science talent.

Below is our list of top employers, that between them, create thousands of life sciences jobs in New Jersey and make the Garden State one of the best places in the world for life sciences talent to thrive.

One of the biggest biopharmaceutical companies in the world, Pfizer is known for best-selling products such as Viagra, Advil and Centrum. The company develops drugs and treatments in many therapy areas such as oncology, rare disease and metabolic disease, with a particular focus on vaccines and medicines that can prevent disease. Pfizer has four offices in New Jersey - Madison, Peapack, Morristown and West Trenton – that employ 2,000 life science professionals according to recent reports.  

• Stryker (Orthopaedics)

Stryker is a US medical device company headquartered in Kalamazoo, Michigan. The company spent an impressive $715 million on research and development in 2016, and its products reached patients in over 100 countries worldwide. Stryker is regularly voted a top employer, receiving recognition as the best workplace for millennials, women, parents and LGBT equality . The company develops reconstructive, surgical, and neurotechnology and spine products in an effort to improve global healthcare. The company has a manufacturing site in Mahwah, NJ, called Stryker Orthopaedics, as well a surgical supply store in Allendale. In 2016, Stryker employed approximately 2,080 people in this region.

French company Sanofi is one of the leading pharmaceutical employers in the world, with many subsidiary companies that include biotechnology, consumer good and patient healthcare organisations. Sanofi’s North American headquarters are based in Bridgewater, NJ, as well as the subsidiary, Sanofi Genzyme Biosurgery, which is located in Ridgefield. Combined, 2016 figures showed that Sanofi employees in the New Jersey area totalled 2,443. The company develops innovate drugs and treatments in a wide range of therapy areas including autoimmune diseases, infectious diseases, cardiovascular and metabolic diseases.

• L’Oreal USA. Inc

The world’s largest cosmetics company, L’Oreal has its headquarters in Paris, France. The company is world-famous for its vast array of popular brands including Garnier, Maybelline and NYX Cosmetics. L’Oreal employs 10,000 people who are scattered across Europe, North America, South America and Africa. New Jersey is home to three L’Oreal sites with 2,500 employees (in 2016): a research center in Princeton, a manufacturing site in Somerset and an evaluation center in Clark, NJ.

• Bayer Healthcare

Bayer Healthcare is a German pharmaceutical company that is fast becoming a household name, with many well-known products such as the antihistamine drug Claritin and vitamin supplement Berocca. Bayer employs 12,000 people across six continents, including countries in Africa, South America and South East Asia. Currently, it ranks 8 th on the list of top 10 companies to work for according to Glassdoor . The company’s base in the USA is located in Whippany, NJ, and had approximately 2,800 employees on site in 2016.

Celgene is a global leading pharmaceutical company that has its headquarters in Summit, NJ. The company employs 7,000 people worldwide in more than 60 countries, and specialises in an extensive number of therapy areas including haematology, inflammation, immunology and orphan diseases. Celgene operates all over the USA, but has offices based in New Jersey in Summit, Warren, Berkeley Heights and Basking Ridge.

Swiss pharmaceutical company Novartis is a global provider of breakthrough treatments that reach patients in over 180 countries. Its pipeline features some exciting drugs being developed in immunology and cell and gene therapy. Novartis employs an impressive 181,700 worldwide, and in 2016 there were 5,149 employees spread across multiple sites in New Jersey, in locations such as Princeton and East Hanover.

• Bristol-Myers Squibb

Leading pharmaceutical company Bristol-Myers Squibb has 18 offices based in North America – seven of which are located in New Jersey. In 2016, most of their 6,300 employees based in New Jersey were concerned with research and development (R&D), but others managed commercialization and late-stage development, sales force training and information management. Bristol-Myers Squibb focuses on a broad range of therapy areas including oncology, cardiovascular and immunotherapy, and boasts an impressive and varied pipeline.

• Merck & Co.

Biopharmaceutical giant Merck has its head offices in Kenilworth, NJ, and is the second biggest employer in the region. The company specialises in developing a wide range of drugs and treatments, including vaccines and biological therapies, to combat global unmet medical need. Out of their 68,000 employees worldwide, 9,800 worked at the Merck headquarters in New Jersey in 2016.

• Johnson & Johnson

The biggest life sciences employer in New Jersey is Johnson & Johnson, a biopharmaceutical company headquartered in New Brunswick. The company has been a staple household name for several decades thanks to its vast collection of top-selling drugs and products that are sold in over 175 countries worldwide. There is also a consumer division of the company based in Skillman, NJ, that manufactures over-the-counter goods such as baby, nutritional, skin and hair products. Figures show that J&J had 127,100 employees in total in 2016, 7,437 of which worked in their New Jersey offices.

If you are interested in working for one of the top life science employers in New Jersey, please upload your resume to our website, or apply for job opportunities and our specialist life science recruitment consultants will be able to assist you.

Latest Posts

Infographic: Commanding leadership

by Proclinical Staffing

Infographic: Pacesetting leadership

Infographic: Affiliative leadership

Infographic: Visionary leadership

Who are the top 10 pharmaceutical companies in the world? (2024)

by Hannah Burke

Global Top 10 Animal Health Companies in 2024

Small US-based oncology consulting firm, expanding operations into Europe

Large pharma, AI transformation workforce expansion

Scale up radiotherapy business, technical team build out

Large global biotech, oncology division build in Europe

US$315000 - US$320000 per annum

Boston, USA

Proclinical is seeking a dedicated Executive Director to focus on Translational Immunology. This is a permanent position based in Boston, Massachusetts.

Lawrenceville, USA

Proclinical is currently recruiting for an Outsourcing Manager to join a dedicated team. This is a temporary contract position based in Lawrenceville, New Jersey.

Zug, Switzerland

Proclinical are currently recruiting for a Senior Accountant to support the company internationally. This is a permanent position based in Zug, Switzerland.

Wettenberg (35435), Germany

Für unseren Kunden, ein international tätiges Pharmaunternehmen und Top-Player im Bereich Gastroenterologie, suchen wir zum nächstmöglichen Zeitpunkt eine/n

Proclinical rekrutiert Mitarbeiter in der Feststoffproduktion (m/w/d) für eine befristete Anstellung in Deutschland.

Basel, Switzerland

Proclinical is currently recruiting for a Clinical Packaging Operator for a temporary contract position based fully on-site in Basel, Switzerland.

Proclinical is currently recruiting for a Lab Scientist for a temporary contract role with a focus on Biologics Development. This 12-month contract is based fully on-site in Basel, Switzerland.

US$25.00 - US$30.00 per hour

Cambridge, USA

Proclinical is seeking a dedicated and detail-oriented Senior Associate Scientist to support stability and specification tasks for siRNA drug substances and drug products.

Career advice

• Proclinical Staffing
• Proclinical Consulting
• Proclinical Executive
• Proclinical Engage
• Job Opportunities
• Our Services
• Submit vacancy
• Insights and Advice
• Meet the Team

Register a new account

• Modern slavery agreement
• Gender pay gap
• Privacy policy
• Carbon Reduction Plan PPN 06/21

Sign up for free THTR email newsletter

• Top Companies
• Latest News

The Top 25 Healthcare Technology Leaders of New Jersey for 2023

The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of New Jersey for 2023. Home to more than 22,645 healthcare establishments, New Jersey is a hotbed for cutting-edge research and treatment in the medical and life sciences fields. In fact, the healthcare industry plays a vital role in the prosperity of the Garden State's economic well-being, contributing $37 billion to the state's economy each year. This is bolstered by New Jersey's 42 teaching hospitals and 5 medical schools that are preparing the medical practitioners and researchers of the future. In recognition of the state's many achievements, this year's list honors some of the most influential thought leaders within New Jersey's booming healthcare technology industry.

An excellent example of an outstanding healthcare technology leader is Pavan Handa, the SVP of Strategic Portfolio Management for Amneal Pharmaceuticals. With more than 25 years of experience in the global biopharmaceutical industry, Handa has generated multi-billion dollars' worth of value through strategic alliances, licensing, M&A, and commercialization of new ventures. Meanwhile, Sheri Lydick is leading BioAtla as its Chief Commercial Officer, having previously worked at numerous top healthcare companies–and notably spearheaded the U.S. launch of the multi-billion dollar drug, Otezla. Lastly, Douglas Beck, is among the most prolific authors in audiology with more than 208 publications. Today, he serves as the Vice President of Clinical Sciences at Cognivue, which provides the world's first FDA-cleared computerized test of cognitive function.

Please join us in celebrating The Top 25 Healthcare Technology Leaders of New Jersey for 2023.

Steve Cutler was appointed Chief Executive Officer of ICON in March 2017, having previously served as Chief Operating Officer for three years. Cutler joined ICON as Group President, Clinical Research Services in 2011–and has been a member of the board since November 2015. As CEO, Cutler has overseen a period of significant progress for ICON, driven by both strong organic growth and a number of strategic acquisitions, including PRA Health Sciences in 2021. Notably, ICON is the world’s leading clinical research organization. From molecule to medicine, the company advances clinical research by providing outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations. With headquarters in Dublin, Ireland, ICON employs approximately 41,150 employees in 53 countries.

Throughout his career in the clinical research and pharmaceutical industries, Cutler has held numerous senior leadership positions. These include Chief Executive Officer of Kendle, Senior Vice President, Global Project Management at Quintiles (now IQVIA) and Senior Vice President, Clinical, Medical and Regulatory, also at Quintiles. Prior to joining Quintiles, Cutler worked with Sandoz (now Novartis) in Australia and Europe. He holds a B.Sc. and a Ph.D. from the University of Sydney. He also holds an MBA from the University of Birmingham (UK).

Steve Cutler’s Insight:

“At ICON, we work to improve the lives of patients by accelerating the development of our customers’ drugs and devices. We do this by delivering industry-leading solutions and best-in-class performance in clinical development. This is achieved through our dedicated and resourceful people in addition to our work practices and the use of innovative technologies, which drive positive outcomes for our customers.”

Kathryn Wengel is Executive Vice President, Chief Technical Operations & Risk Officer for Johnson & Johnson. She is also a member of the company’s Executive Committee. She has significant healthcare, operations, and global business expertise – with more than three decades of experience in leadership positions at Johnson & Johnson. In her current role, Wengel is responsible for the continued strengthening of the Company’s core technical operations and risk management capabilities. 

Most recently, Wengel served for nine years as Executive Vice President and Chief Global Supply Chain Officer. Prior to that, she served as the company’s first Chief Quality Officer. Under her leadership, Johnson & Johnson has become the only healthcare company ever ranked among the top five on the Supply Chain Top 25 list by Gartner, Inc. – a ranking that recognizes the critical role its Supply Chain has played as an integrator across an ecosystem of internal and external partners.

Externally from Johnson & Johnson, Wengel serves as a member of the Board of Directors at the Laboratory Corporation of America Holdings (Labcorp), a leading global life sciences company. She is the Vice Chair of the Board of Directors at the National Association of Manufacturers in the U.S. She also serves as Chair of the Board of GS1 Global, a nonprofit that develops and maintains global supply chain standards. Within Johnson & Johnson, Wengel is executive sponsor for the Women’s Leadership & Inclusion initiative and the Women in Science, Technology, Engineering, Math, Manufacturing and Design program. Wengel holds a BSE degree in civil engineering and operations research from Princeton University.

E. Garrett Ingram is the Chief Executive Officer of Cipla Therapeutics. She first joined the company in 2019. Cipla Therapeutics is the specialty business of Cipla, a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Their credo and their purpose of ‘Caring for Life' continues to guide their actions towards their people and the planet for creating a sustainable future. Cipla today has a presence in 80+ countries–providing over 1,500 products across various therapeutic categories in 50+ dosage forms.

Previously, Ingram was a CMO at MannKind Corporation. Before that, she served as an SVP of managed markets at Dexcom. Earlier in her career, she worked with Novo Nordisk Pharmaceuticals as an AVP of managed markets strategy & operations. Ingram earned a master's from the University of South Carolina and an undergraduate degree from East Carolina University.

Bijoy Sagar is Executive Vice President and Chief Information and Digital Transformation Officer of Bayer, a global enterprise with core competencies in the life science fields of healthcare and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

Prior to joining Bayer, Sagar served variously as the Chief Digital Technology Officer and CIO of Stryker, a leading medical technology company, where he was also a member of the executive team. Sagar has over 20 years of experience in the healthcare and chemical sectors. He has previously worked for pharma and biotech companies in the USA and Europe, including Millennium Pharmaceuticals (now Takeda), Amgen, Eli Lilly & Company, and Merck KGaA. He also serves on various advisory councils and boards. Sagar holds master's degrees from the University of Mumbai and Northeastern University, Boston. He also holds US citizenship.

Bijoy SagarInsight

"Through innovative healthcare solutions powered by cutting-edge technology, Bayer is driving the future of healthcare forward, empowering patients and healthcare professionals alike with accessible, efficient, and effective tools to improve lives and transform outcomes – in the purpose of ‘Health for all, hunger for none.’”

Joseph Wolk is the Executive Vice President and Chief Financial Officer for Johnson & Johnson. Wolk also serves as a member of the company’s Executive Committee, playing a strategic role in the overall management of the organization and leading the development and execution of the business’ global long-term financial strategy. He leads the worldwide Finance and Global Services organizations, which includes approximately 9,000 colleagues around the globe. He has been with Johnson & Johnson for 25 years, having assumed his CFO position in 2018.

Earlier, Wolk was the Vice President of Investor Relations for Johnson & Johnson. In this role, he developed a winning strategy for building strong relationships with the investment community and disseminating Johnson & Johnson’s value creation narrative to all external financial stakeholders. Notably, during Wolk’s tenure, the Investor Relations function was regularly recognized by Institutional Investor as one of the best teams in the industry. Before that, Wolk held a variety of senior leadership roles in several sectors and functions across the company.

Wolk is an accomplished, Credo-based leader; passionate about talent development, driving innovation, and community service. He is the executive sponsor of Johnson & Johnson’s Impact Venture Fund, the executive sponsor of the Veterans Leadership Council and a champion of the Finance Leadership Development Program, and a member of the Stanford Medicine Board of Fellows, the CNBC Global CFO Council and the Wall Street Journal CFO Network. Wolk holds a BS in Finance from St. Joseph’s University, where he was recently inducted into the University’s Haub School of Business Hall of Fame. He also holds a JD from Temple University School of Law and is a CPA.

Will Lewis joined Insmed in 2012 as President, Chief Executive Officer, and member of the board of directors. He became Chair of the Board of Directors in November 2018. Lewis is also the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals. Before that, he spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government.

Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The company’s first commercial product is a first-in-disease therapy –approved in the United States, Europe, and Japan– that treats chronic, debilitating lung disease.

Away from Insmed, Lewis serves as Chair of the Board of Directors of Adrestia Therapeutics, a private UK-based company focused on synthetic rescue therapies for genetic diseases. Furthermore, he is a member of the Board of Trustees of Case Western Reserve University; and a member of the Board of Trustees of BioNJ, the life sciences association for New Jersey. Lewis holds a Bachelor of Arts, cum laude, from Oberlin College. He also holds an MBA and JD, with Honors, from Case Western Reserve University.

Will Lewis Insight

“Insmed is at a pivotal moment in our history as we prepare to read out key data from across our four pillars over the next 12 months and advance our early-stage research engine, which now includes cutting-edge AI-driven protein engineering, gene therapy, and protein manufacturing. I am proud to lead one of the most talented teams in our industry—now more than 800 employees strong—as we embark on this transformation and prepare to serve significantly more patients while delivering the next generation of potentially first-in-class, first-in-disease, and best-in-class medicines. As we grow and evolve, our singular focus remains on developing and delivering therapies for patients with rare and serious diseases who currently face significant unmet needs, regardless of modality or therapeutic area.”

Kendra Rose, PhD, is Vice President and Head of New Platforms, Ophthalmology and Hemophilia in the Business Development & Licensing and Open Innovation (BD&L/OI) function for the Pharmaceuticals Division at Bayer. In this capacity, Rose and her team are responsible for identifying innovative collaboration opportunities to further strengthen Bayer’s strategies in new platforms–such as cell & gene therapy; as well as ophthalmology and hemophilia.

Rose joined Bayer in 2015 and worked in New Product Commercialization and Global Strategic Marketing with responsibilities for commercial input for the internal and external pipeline. Rose then joined BD&L/OI, leading the New Business Development team and developed valuation models, provided commercial input, and evaluated all pharmaceutical deals.

Before joining Bayer, Rose worked at Novartis in Global New Products. She subsequently led the global launch for a heart failure drug. Rose started her career at Johnson & Johnson Consumer Products in R&D and went on to work in various roles for US marketing in its medical device sector. Later worked in a cross-sector Innovation role. Rose holds a PhD in Chemistry from Stanford University and an MBA from The Wharton School, University of Pennsylvania.

Bayer’s Insight

“Our Business Development & Licensing /Open Innovation function is focused on creative collaboration models that foster innovation. The aim is to bring brilliant minds together to solve some of the world’s toughest challenges for the benefit of the patients and our collaboration models allow us to enable that in a creative, flexible and agile way.”

Evelyn Douglas joined Convatec and their Executive Leadership Team in November 2020 as Chief of Corporate Strategy and Business Development. Later, in April 2021, she assumed the roles of General Counsel and Company Secretary. Douglas has deep expertise in the MedTech sector, having spent twenty years at Becton, Dickinson and Company prior to joining Convatec.

ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key business units–Ostomy Care, Wound Therapeutics, Continence and Critical Care and Infusion Devices–ConvaTec products support healthcare professionals from the hospital to the community health setting.

At BD, she was Senior Vice President of Corporate Development and Strategy. During this time, she helped the company build its capabilities around corporate development and strategy, and assisted the global business units in strengthening their strategic focus and pursuing opportunities for partnerships, acquisitions and divestitures. Prior to her role in corporate development at BD, Douglas held positions of increasing responsibility in the BD Law Group. She began her career at White & Case in New York. She holds a JD from Harvard Law School and a bachelor’s, with Honors, in Political Science from Williams College, Massachusetts.

“At Convatec, we’re pioneering trusted medical solutions to improve the lives we touch. Each and every day, our employees are bringing our forever caring promise to life for the benefit of customers, patients and healthcare professionals around the world. We’re exceptionally proud of our teams here in New Jersey, and I’m grateful for this recognition on their behalf.”

Curt Bashford is the CEO of General Devices, a 40+ year medical technology company that specializes in mobile telemedicine and telehealth that enables simply smarter patient care by empowering hospitals, EMS, mobile integrated healthcare, community paramedicine and public safety responders with the most comprehensive, highly configurable, and affordable medical team communications solutions. Bashford has 37 years of experience. He began his career in 1986.

Bashford graduated from New Jersey Institute of Technology with a master's in bio-medical engineering. Earlier he received his undergraduate degree in electrical engineering.

Curt Bashford Insight:

"Out of hospital healthcare delivery is evolving and at General Devices (GD), we are proud that our responsive innovations help hospitals and emergency medical services deliver better, more timely patient care. Our mobile telehealth and communications solution impacts the lives of tens of thousands of patients every day across the country."

Gary Palmer is the Senior Vice President of Global Immunology & Fibrosis of Bristol Myers Squibb, a global biopharmaceutical company headquartered in New York City. With a rich history dating back over a century, BMS is renowned for its commitment to discovering, developing, and delivering innovative medicines that address serious diseases. The company focuses on areas such as oncology, immunology, cardiovascular disease, and neuroscience. BMS has a diverse portfolio of products, including blockbuster drugs like Opdivo, Eliquis, and Orencia, which have significantly impacted patient care worldwide. It also engages in strategic collaborations and acquisitions to enhance its research and development capabilities, expand its product offerings, and strengthen its global presence. Palmer has 31 years of experience. He began his career in 1992.

Before joining Bristol Myers Squibb, Palmer was an SVP of global & US medical affairs at Myovant Sciences. Before that, he served as the SVP of head of medical affairs at Actelion, a Janssen Pharmaceuticals Company of Johnson & Johnson. Earlier in his career, he worked with Merck as a country medical director. Palmer graduated from the University of the Witwatersrand - Johannesburg with an MBA in General Business Administration, with a MD, and with an undergraduate degree in medicine and surgery.

Gary Palmer’s Insight

“ I am proud to be working at a world leading biopharma company, with the inspiring vision to transform patients’ lives by addressing unmet medical needs in people living with immune-mediated diseases”

Brian Hilberdink is the Executive Vice President of LEO Pharma’s North America Region. In March 2022, he embraced a once-in-a-lifetime opportunity to join LEO Pharma during a significant transformation in the company’s 113+ year history. Notably, LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. With the approval and launch of LEO Pharma’s first biologic agent, the ambition is to turn the US business into the primary global growth engine ahead of a potential IPO.

Prior to LEO Pharma, Hilberdink spent over 25 years with Novo Nordisk, most recently serving as a Senior Vice President for the commercial organization in the US. During his long tenure with the company, he also served as President of Novo Nordisk Canada Inc.; and Corporate Vice President in Global Marketing of Novo Nordisk A/S in Denmark, where he led the launch of the company’s next generation insulin portfolio.

Brian Hilberdink’s Insight

“LEO Pharma has a long history of helping people achieve healthy skin, and I am honored to lead the company’s growth journey in the U.S.,”

“With our pioneering spirit and innovative mindset, we are laser focused on making a difference for patients and healthcare providers and becoming a global leader in medical dermatology.”

DB Kartik is the President and Chief Operating Officer at CorEvitas, LLC, a science-led data intelligence company that provides the life sciences industry with the objective data and clinical insights needed to demonstrate real-world safety, effectiveness, and patient outcomes in the post-approval setting.

Kartik is a purpose-driven executive with global experience in the healthcare industry. He has a successful record in diverse operating environments, including major divisions of publicly traded multi-national and middle market growth companies.

Notably, Kartik has more than 25 years of experience in global leadership roles in the healthcare and energy industries. Before joining CorEvitas, he was the Head of Financial Planning and Operations at Cubist Pharmaceuticals. He holds an MBA and CFA from ICFAI Business School, India.

DB Kartik Insight

"CorEvitas is the built-for-purpose provider of gold-standard real-world evidence. With 20 years of experience in specialized patient registries and curated data sources, we build on our strengths in comparative effectiveness research and drug safety studies to advance patient care by generating real-world insights into health conditions."

Helen Yeardley is the Global Clinical Operations Head at ICON. In this role, she oversees a team of approximately 4,000 staff in areas including clinical and hub monitoring, clinical risk management, and trial master file services. With over 25 years of experience in monitoring and managing clinical trials–in both CROs and large pharma companies–Yeardley has held numerous senior positions in the areas of feasibility, site identification and start-up, clinical operations, clinical trial management and project management, both in early and late phase drug development. She started her career as a CRA. Her therapeutic background is in oncology as well as internal medicine.

Yeardley’s company, ICON, is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, the company advances clinical research by providing outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations. It develops new innovations, drives emerging therapies forward, and improves patient lives. With headquarters in Dublin, Ireland, ICON employs approximately 41,150 employees in 53 countries.

Helen Yeardley’s Insight

“At ICON, we see a huge opportunity to apply new thinking and to capitalize on technology and digital advancements in a number of areas to accelerate high quality clinical trials, including patient enrolment, site performance management, risk management, remote monitoring and remote data collection. I think we can drive real and positive progress in these areas – it is an exciting and rewarding time to be working in clinical research.”

Joining the company in 2018, Lars Birgerson is the President and Chief Medical Officer for Adlai Nortye, a global clinical stage biotechnology company focused on developing innovative cancer therapies to help patients live better lives. The company has 6 drug candidates under development–of which no less than 3 are in clinical stage. The clinically most advanced compound AN 2025 is in a global phase III trial for treatment of Metastatic Cancer of the Head and Neck in patients who have progressed after checkpoint Inhibitor treatment.

Previously, Birgerson was Senior Vice President of Medical Research and Development at Bristol-Myers Squibb. Before that, he built and led the Global Medical Affairs function of Roche and the Medical Affairs function of Genentech. Birgerson received his M.D., Ph.D. and completed residencies in Obstetrics & Gynecology, General Surgery, Gynecological Oncology and Urological Surgery at Uppsala University in Sweden.

Kimball Hall is the Chief Executive Officer of Innocoll Biotherapeutics, a biopharmaceutical company that specializes in developing and commercializing innovative therapies using its proprietary collagen-based technologies. The company's focus lies in addressing unmet medical needs in areas such as surgical and wound care–with a particular emphasis on the treatment of soft tissue injuries.

Before joining Innocoll Biotherapeutics, Hall was a president and chief operating officer at Abzena. Before that, she served as global head of biologics drug substance at Genentech. Earlier in her career, she worked at Amgen as a senior. director of quality. Hall graduated from the University of Washington with an undergraduate degree in microbiology.

Kimball Hall Insight

"Innocoll Biotherapeutics is dedicated to delivering non-opioid alternatives for postsurgical pain. With our two commercially available products, Xaracoll and Posimir, we are making a difference in patient’s lives. Additionally, Syntacoll, a subsidiary of Innocoll develops, produces, and innovates collagen-based absorbable implants like Xaracoll. I am thrilled to be leading both of our highly innovative teams."

Pavan Handa has over twentyfive years of business development, strategic planning, and venture management experience in the global biopharmaceutical industry with both drug delivery & specialty pharma companies. Throughout his career, he has generated multi-billion dollars' worth of value through strategic alliances, licensing, M&A, and commercialization of new ventures. Currently he is the SVP, Strategic Portfolio Management for Amneal Pharmaceuticals, a fully integrated company focused on the development, manufacturing, and distribution of generic and specialty drug products with $2 billion in annual sales.

Prior to Amneal, he was EVP and CBO for Kashiv Pharma. Notably, he led the due diligence in the acquisition of Kashiv by Amnea. Before that, he served as SVP of Business Development at Antares Pharma, & VP of Business Development & Alliance Management at Noven Pharmaceuticals, where he diversified the product, revenue, and strategic partnership base, significantly increasing the market valuation of both companies. His achievements at Antares include completing strategic deals with Actavis, Pfizer, Teva, LEO, and Daewoong. His achievements at Noven include completing partnering deals with Shire, Endo, Novartis, and P&G–raising over $250 million in upfront and licensing revenue, acquiring a CNS specialty pharma, and the eventual sale of Noven to Hisamitsu for $450 million.

Prior to joining Noven, Handa served as SVP of Business Development & Portfolio Management at Pharmacologics LLC, a drug development venture capital affiliate of MDS Inc. Additionally, he has held senior business development positions at Enzon Pharmaceuticals and Union Carbide Corporation, where his contributions included the creation of a $500 million VC fund, generating $200 million in licensing revenues, and implementing acquisitions worth over $100 million. Handa graduated from the University of Cincinnati with an MBA and from Delhi University with an undergraduate degree in economics and mathematics.

“Amneal, a diversified biopharmaceutical company with annual revenue of about $2.3 billion, is growing its specialty portfolio & development pipeline utilizing advanced drug delivery technologies to provide innovative and accessible medicines in CNS, endocrine disorders, oncology, and rare diseases.”

Tom Blount serves as the SVP, President, North America of Embecta. Formerly part of BD, Embecta is a global medical technology company singularly focused on improving the lives of people living with diabetes. For nearly 100 years, they’ve been developing and providing solutions to the diabetes community. They are the leaders in insulin delivery, with more than 30 million people in over 100 countries relying on their pen needle and syringe products.

Previously, Blount spent six years with Becton, Dickinson and Company (BD) as VP/GM US region Diabetes Care, WW VP/GM Infusion, and Global Marketing leader for Diabetes Care and additional upstream marketing roles. Before BD, Blount spent 16 years at Sanofi in various roles, including Associate VP of Diabetes Value and Access, Associate VP of Toujeo Value & Access, Associate VP Lixisenatide Family Marketing, Sr. Director of Marketing Strategy for Sanofi Genzyme R&D, Sr. Director of Marketing Strategy for the Fibrosis Wound Repair Global Strategy Unit, Director of General Therapeutics Mature Brands, Director & Commercial Alliance Leader for XYZAL Marketing, and many other roles in Sales and Marketing.

With extensive experience in launching products, Blount has held numerous roles in sales, marketing, and market access across various disease areas, including diabetes. He also spent 5 years on active duty in the United States Army, finishing as a Captain. He holds a Bachelor of Science in German/French from the United States Military Academy at West Point. He also holds a Master of Science in International Relations from Troy University – European Campus.

Tom Blount Insight

“I’m grateful to The Healthcare Technology Report for recognizing me as a Top 25 Healthcare Technology Leader of New Jersey for 2023. I am honored to help lead the charge in developing growth platforms for a company like Embecta, prioritizing innovation in the marketplace. Our team is dedicated to empowering people living with diabetes through cutting-edge products, and I am proud to be a part of this shared mission.”

As an Executive Vice President of Technology at Framework Solutions, Michael Scalea has led the company in new areas of technology services, providing technology solutions and innovation in all areas of digital transformation. It is worthy to note that Framework Solutions is a leading business consulting firm that provides Clinical to Commercial Solutions to Life Sciences companies with the goal of accelerating customer success with strategic and tactical solutions in the areas of Medical Affairs, Regulatory Solutions, MLR Solutions, Commercialization, and Technology. The company provides a high quality of services to over 225 clients, ranging from emerging biotech to large pharma. Through its specialized knowledge and services, the organization plays a crucial role in advancing the development and delivery of innovative solutions that improve the overall well-being of individuals and animals in their care.

Scalea has more than 25 years of experience within the Life Sciences industry. Prior to joining Framework Solutions, he built and led a Global Veeva and Salesforce practice, as a Principal at Capgemini. He spearheaded implementations and managed services for the top 10 pharmaceutical companies. Earlier in his career, he worked as a consultant, and was a Director at Pfizer for 10 years. Scalea holds a Bachelor of Science in Computer Science from Seton Hall University, as well as an MBA from Walden University.

Framework Solutions Insight

“We enable Life Sciences companies to navigate the digital era and leverage innovative technologies to optimize process, enhance efficiencies, and deliver transformative solutions that amplify their impact and drive progress in human health and animal care.”

Sheri Lydick is the Chief Commercial Officer at BioAtla, a San Diego-based biotechnology company focused on development of antibody therapeutics using their proprietary Conditionally Active Biologic (CAB) technology. With over 20 years of leadership and commercialization experience in the biotechnology and pharmaceutical industry, Lydick leads the company’s portfolio and commercial planning, including assessment and execution of strategic business opportunities, development of commercialization plans and build out of commercial infrastructure in preparation for global launches of these novel CAB therapeutics in multiple solid tumor types. Additionally, Lydick leads investor engagement and marketing of the company to investors, analysts, and shareholders.

In her prior role at Bristol-Myers Squibb, Lydick was Vice President, Commercial Lead and was responsible for building the sales and marketing teams and leading the commercial launch of Zeposia® across multiple therapeutic areas (multiple sclerosis and ulcerative colitis). In her twelve years (2007-2019) at Celgene, Lydick held positions of increasing responsibility–and was instrumental in building the Inflammation & Immunology franchise, establishing markets of focus, defining resource and capability requirements to support global launches into competitive markets, and leading the US launch of the multi-billion dollar drug, Otezla®. Notably, Lydick received both her BSc degree in Zoology and a Master of Science degree in Biochemistry and Molecular Biology from the University of Maine.

Sheri Lydick Insight

“BioAtla is the inventor and leader in the development of proprietary Conditionally Active Biologics (CAB) technology, creating antibodies that only bind to cancer cells not healthy cells. Currently, we have four CAB antibodies in clinical development across multiple solid tumors. Importantly, all of our programs are focused on providing novel cancer therapies for patients with high unmet medical need.”

Mahavir Prashad is the SVP and Head of Chemical Development Solutions of Aragen Life Sciences. Prashad comes with over 37 years of experience in chemical and analytical development–with an emphasis on quality and cGMP compliances. His expertise lies in leveraging green chemistry principles and modern technologies in API synthesis. Prashad has led several projects to develop safe, economical, and ecologically cleaner processes for large-scale synthesis of Active Pharmaceutical Ingredients (APIs) for marketed products.

His company, Aragen, is a trusted R&D and manufacturing partner to the global life sciences industry. From concept to commercial, the company transforms your ideas into solutions for better health. Whether large pharma or biotech, an agrochemical or animal health company, Aragen provides global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules.

Prashad has a strong scientific track record to his credit, including 94 publications, 4 review articles, 1 book chapter, 71 patent applications, and 10 lectures at scientific conferences. Prior to joining Aragen, he worked with Novartis and Sai Life Sciences. Prashad earned a Ph.D. in organic chemistry from Central Drug Research Institute (CDRI), CCS University.

Mahavir Prashad Insight

“In every molecule is the possibility for better health”.

Zeil Rosenberg, MD, MPH, joined Tonix as Executive Vice President, Medical in January 2023. In this role, Rosenberg is responsible for leading Tonix’s clinical development efforts for vaccines and antivirals. This includes overseeing the clinical development of Tonix’s vaccine for smallpox and monkeypox, TNX-801; the vaccine for COVID-19, TNX-1850; and the antiviral anti-SARS-CoV-2 spike protein monoclonal antibodies, TNX-3600 and TNX-3800–to protect immunocompromised individuals from severe COVID-19. Rosenberg brings to Tonix’s clinical team expertise as an infectious disease drug developer.

He was most recently at PPD, part of Thermo Fisher Scientific, serving as Executive Director, Biotech and as Therapeutic Area Head for Vaccines at its Accelerated Enrollment Solutions Group, where he provided leadership on multiple successful COVID-19 vaccine clinical trials. At BD, he was Worldwide Business Leader and Medical Director for Immunization; and was Vice President for Medical Affairs at Admera Health. He was key to the launch of a global public private partnership, including UNICEF and WHO, to help eliminate maternal and neonatal tetanus through immunization, resulting in the significant reduction of neonatal mortality. Previously he also served as National Immunization Advisor to the Indonesian Ministry of Health in Jakarta; and as Chief Technical Officer for Immunization at USAID, Washington, D.C.

Rosenberg received his BA with Honors and Distinction at Stanford University; earned his MD at the University of California, San Francisco; and completed his internship and residency at Mount Sinai and Cornell University Medical College, respectively. He holds a Masters of Public Health from Columbia University. Furthermore, Rosenberg is an elected Fellow of both the American College of Preventive Medicine and the New York Academy of Medicine, and Specialty Fellow of the American Academy of Pediatrics. He has served as AAS Science, Engineering and Diplomacy Fellow.

Zeil Rosenberg’s Insight

“Tonix is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies to improve population health. At Tonix, we are translating our deep understanding of biology and disease pathology into potential treatments across multiple therapeutic areas, including important Central Nervous System conditions like fibromyalgia, depression and migraine. Through our broad in-house capabilities and strategic collaborations with world-class academic institutions and non-profit research organizations, we strive to bring novel therapeutics to the patients who need them most.”

Christopher Jones is the SVP of Scientific Partner of ApotheCom. He first joined the company in 2019 as VP of scientific services. ApotheCom is a Global Medical Communications powerhouse with offices in London, Leeds, Yardley, New York, San Francisco, San Diego, Boston, Lebanon, Auckland, Tokyo, and Johannesburg. Their mission is to be an effective and proactive broker of collaborative and sustained engagement for the healthcare community, to drive meaningful change, and positive outcomes. ApotheCom is uniquely able to create and deploy teams across many geographies, pulling on specialized skills and specific market expertise. The team comprises 130 PhDs and PharmDs–and more than 250 content developers who understand how to tell the scientific, clinical, and value stories to reach specific audiences.

Previously, Jones was a senior director of clinical oncology lead at MedErgy; and before that an associate scientific services director at Wolters Kluwer Pharma Solutions. Earlier in his career, he worked with PharmaWrite LLCPharma as a medical writer. Jones earned a PhD in Molecular Genetics from Swansea University and an undergraduate degree in biochemsitry from Cardiff University / Prifysgol Caerdydd.

Christopher Jones Insight

“ApotheCom is a strategic powerhouse with a deep heritage, qualified experts, and refined processes. Our mix of medical experts and technological and creative agility provide integrated solutions to support medical affairs across product life cycles.”

Dhaval Desai, PharmD, is Senior Vice President and Chief Development Officer at IVERIC Bio, a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

Desai joined Iveric Bio as Chief of Staff in 2020 after serving as Vice President and Medical Unit Head of US Ophthalmics at Novartis. Under Desai’s leadership, Iveric Bio has achieved key goals, including receiving positive results from its pivotal clinical trial program and FDA Breakthrough Therapy designation for avacincaptad pegol in geographic atrophy.

Prior to Novartis, Desai was a Chief Strategy Officer at Aerpio Therapeutics; and a Global Director, Medical Affairs at ThromboGenics. Earlier in his career, he also worked with Sanofi and Onyx Pharmaceuticals. Desai graduated from Rutgers University with a PharmD.

Dhaval Desai Insight

“I am honored by this recognition as it reflects the hard work and energy that our team at Iveric Bio is dedicating to addressing unmet needs for people with retinal diseases. We see a world where vision is preserved, and I look forward to pioneering transformational therapies to make that vision a reality.”

Kiran Gande is the VP of Regulatory Affairs and Pharmacovigilance of Leading Pharma, a privately-owned generic pharmaceutical company that purchases, licenses, develops, manufactures and distributes high-quality, safe and effective products. Their clients include drugstore chains, distributors, wholesalers, mass merchandisers, government agencies, and managed care accounts. The company's corporate headquarters are located in Fairfield, NJ –which is also the site of the company's 53,000 square-foot manufacturing facility. Milestones for Leading Pharma include successfully developing and implementing regulatory strategies to facilitate the approval and commercialization of wide variety of therapeutic range of products, including Antidepressants, Anticancer, Antihypertensive, Antipsychotic and Antiemetic, Anti-diarrheal, among many others.

Gande first joined the company in 2016 as associate director of regulatory affairs and pharmacovigilance. Prior to that, he was a quality assurance and analytical assurance at AstraZeneca, which was preceded by serving as a head of QA and RA at Appco Pharmaceuticals. Earlier in his career, he worked with Aurobindo Pharma as a senior quality assurance executive. Gande earned an MPharm from Rajiv Gandhi University of Health Sciences and an undergraduate degree in pharmacy from Bangalore University.

Douglas Beck is the Vice President of Clinical Sciences of Cognivue, a provider of a risk assessment test that identifies changes in cognitive function that could be indicative of early dementia or Alzheimer's Disease. It is the world's first FDA-Cleared computerized test of cognitive function.

Beck began his professional career at the House Ear Institute (Los Angeles), where he focused on cochlear implant research and intraoperative cranial nerve monitoring. In 1988, he became Director of Audiology at Saint Louis University. In 1996, he co-founded a multi-office dispensing practice in St Louis. In 1999, he became President and Editor- In-Chief of AudiologyOnline.com and SpeechPathology.com. From 2008 through 2015 he served as Web Content Editor for the American Academy of Audiology (AAA). In 2016 he was appointed Senior Editor for Clinical Research at the Hearing Review and was appointed Adjunct Clinical Professor of Communication Disorders & Sciences at State University of NY at Buffalo. In August 2005 he joined Oticon Inc. In 2019 he was appointed Vice President of Academic Sciences at Oticon. After 17 years with Oticon, Beck retired on March 4, 2022.

Beck currently consults, lectures, teaches, volunteers, and writes for multiple audiology, science, medical, and health-related professional organizations globally. He is among the most prolific authors in audiology with more than 208 publications.

Douglas Beck Insight

"For many providers and patients, cognitive health has become increasingly important. The most important factor for potentially changing the trajectory (with regard to cognitive health & decline) is early detection. Cognitive screeners are fast, accurate and pragmatic. Within 10-12 minutes one can assess executive function, memory and visuo-spatial ability, and have a printed report for the physician, to decide if/when a diagnostic cognitive assessment is appropriate. The Lancet 2020 (Livingston and colleagues) reported some 40% of dementia risk is potentially modifiable, and the single largest potentially modifiable risk factor was determined to be untreated hearing loss."

RELATED ARTICLES MORE FROM AUTHOR

Certara to Acquire Cheminformatics Leader Chemaxon

Stryker to Acquire AI-Powered Healthcare Innovator care.ai

Starbucks Expands Greener Stores Initiative

Innovent Biologics Partners with WeComput to Enhance AI Drug Discovery

Vertex Pharmaceuticals Advances Suzetrigine for Acute Pain Treatment

Flo Health Achieves Unicorn Status with $200M Investment

Digital Channels Shape Healthcare Choices: US Consumers Increasingly Rely on Online Information

Inspire Medical Systems Secures FDA Approval for Next-Gen Neurostimulator

PENTAX Medical’s Duodenoscope Receives FDA Clearance

Microsoft Partners with Leading Medical Systems to Enhance AI in Radiology

Teladoc Health Expands Virtual Mental Healthcare for Children and Families Through Partnership with Brightline

Adobe Enhances Educational Offering with New AI Features in Adobe Express for Education

Popular articles.

The Top 50 Healthcare Technology CEOs of 2022

The Top 25 Women Leaders in Biotechnology of 2022

The Top 100 Healthcare Technology Companies of 2022

The Bargain Genome: Illumina Cuts Price to $200 With New Sequencer Machines

The Top 25 Women Leaders in Consumer HealthTech of 2022

The Top 100 Healthcare Technology Companies of 2021

Two Big-Hit Breast Cancer Drug Trials Add to AstraZeneca’s Streak

Voice Analysis AI for Mental Health

The Top 25 Women Leaders in Medical Devices of 2022

• Award Usage
• Manage Subscription --> Contact Us

Coriell Institute

• Request a Quote

HOW CAN WE HELP?

Our expert labs have solutions for your Biobanking , Stem Cell , and Genomic Research needs.

NEED SAMPLES?

Browse our entire collection of Cell Lines , Stem Cells , and DNA & RNA .

From the Camden Cancer Research Center to the Camden Opioid Research Initiative , Coriell scientists are investigating the many ways our DNA impacts human health.

Coriell's labs offer a vast array of services to answer your team's needs. Learn more about our custom services.

• Camden Cancer Research Center

Connecting scientists and empowering collaborative research to develop the next generation of cancer treatments

• Core Facilities

Leverage our expertise and state-of-the-art facilities to accelerate your biomedical research initiatives

This is a dynamic query of 1000 Genomes Project whole genome sequencing data

How Can We Help?

Click here to send us a message, and we'll work together to find a solution.

FEATURED PRODUCTS AND SERVICES

Gold standard practices in cell line establishment, cell characterization and cryopreservation

iPSCs are valuable for their potential for disease pathology research and highly targeted therapies

DNA & RNA

High-quality biomaterials from our Molecular Biology Laboratory

• Allen Cell Collection
• Rett Syndrome iPSC Collection
• Autism Research Resource
• HD Community Biorepository
• CDC Cell and DNA
• J. Craig Venter Institute
• Orphan Disease Center Collection
• All Biobanks
• Meet Our Scientists - Faculty
• Epigenetic Therapies SPORE
• Epigenomics
• Camden Opioid Research Initiative (CORI)
• The Issa & Jelinek Lab
• The Jian Huang Lab
• The Luke Chen Lab
• The Scheinfeldt Lab
• Coriell Personalized Medicine Collaborative (CPMC)
• Publications
• Clinical Trial Support and Biobanking
• Genomic and Epigenomic Services
• Bioinformatics
• DNA and RNA
• Genomic Data Search
• Rare Diseases
• Gene Variants, Mutations
• Search by Catalog ID
• Search Help
• Create Account
• Order Online
• Ordering FAQ
• MTA Assurance Form
• Shipment Policy
• Contact Customer Service
• Our Message
• Your Support in Action
• Make a Donantion
• Our History
• Meet Our Team
• Meet Our Board
• Science Fair
• Summer Experience
• Research Program Internship
• Legal Notice

Our mission is to prevent and cure disease through biomedical research.

CUSTOMER SERVICE [email protected] (800) 752-3805 ● (856) 757-4848

Coriell Institute for Medical Research 403 Haddon Avenue Camden, NJ 08103, USA (856) 966-7377

Ⓒ 2024 Coriell Institute. All rights reserved.

• Employment Opportunities
• Memorials/Tributes
• High School Research Program
• Undergrad Research Program

Every donation will help advance medical research.

Advance. Discover. Educate.

About brinj.

The Biomedical Research Institute of New Jersey (BRInj) is a non-profit medical research organization dedicated to experimental discovery, translational medical science, and the improvement of human health. We are keenly aware of the ever-changing clinical environment, and we recognize the important role that research plays in addressing unmet medical needs.

Dr. Eckman and Dr. Pacheco-Quinto describe their research on Aβ42 fibrillization in synaptic endosomes in the Journal of Neuroscience

Search Cooper

Popular Terms and Topics

• Internal Medicine Residency
• Surgical Critical Care Fellowship
• Gastroenterology Fellowship
• Neurology Residency

Cooper Research Institute

The mission of the Cooper Research Institute is to help foster research within the Cooper Health System by providing the faculty, residents, fellows, nurses, and allied health professionals of Cooper with the support and services required to promote and to successfully develop and conduct investigator-initiated and sponsor-initiated clinical research, and to attract and manage government, foundation, and industry support.

The Cooper Research Institute works in cooperation with Cooper Medical School of Rowan University to foster the growth of student-centric research in the areas of medical education, the science of healthcare delivery and population health, and targeted translational research, capitalizing on the institutional strengths and expertise of both organizations.

Additionally, our research has recently made regional news with the announcement that Rowan University will invest $50 million in research in Camden over a ten-year period, and a large grant from the State of NJ will support collaborative research by CMSRU, Coriell, and Cooper to investigate the genetics of opioid addiction. We are grateful for this tremendous gift from Rowan University and for state support of research endeavors.

Excellence in education, patient care, and research are linked and crucial aspects of the mission of medical schools and academic medical centers. We invite you to explore the following links for a better picture of the depth of educational activities supported by, and scholarly activity generated by, the Cooper University Health Care and Cooper Medical School of Rowan University learning community.

Clinical Research

Southern New Jersey Trauma Research and Treatment Alliance (TRaTa)

Vascular and Endovascular Clinical Trials

Cooper Research Connections

Access is only granted to approved members of the Cooper University Health Care community. To request access, visit research.cooperhealth.org and register your user name and email address. Your request will be reviewed.

South Jersey Medical Report

South Jersey Medical Report is an important resource for physicians for up-to-date news and information about medical and technological advances at Cooper University Health Care. The Report provides information ranging from new physician appointments to clinical trial access to newly available medical procedures for complex patients.

Click here to visit the South Jersey Medical Report site .

Cooper Rowan Medical Journal

Click here to visit the Cooper Rowan Medical Journal site .

Cooper Bridges

Click here to visit the Cooper Bridges site.

Coriell Institute of Medical Research

The internationally acclaimed Coriell Institute for Medical Research, which is affiliated with Cooper, is an independent, not-for-profit research organization dedicated to understanding human genetic diseases and providing the highest quality genetic resources. 

Financial Conflict of Interest Information Disclosure Request

Research projects at Cooper University Health Care (“CUHC”) that are funded by an agency of the Public Health Service (PHS), such as the National Institutes of Health, must ensure public access to certain information about conflicts of interest that have been disclosed to CUHC and reported to the funding agency. U.S. regulations, §50.604, allow anyone to request information about a conflict of interest held by senior or key personnel on a PHS-funded research project. To submit a request, please click here .

Research Labs

• Bhandari Lab
• Bone and Joint Research
• Surgical Research Lab

Med Ed Blogs

Hospital Main Number

856.342.2000, main hospital website.

COOPERHEALTH.ORG

This site uses cookies

We respect your privacy. Cookies help us give you a better experience on our site. By continuing to use this website, you accept and agree to such use of cookies.

Click here for information on how we use cookies.

Tired of Typing? Let's Talk.

Call 1.800.8.COOPER to speak with a Cooper representative who can answer your questions, schedule appointments and register you for classes, events and support groups.

Representatives are available Monday through Friday from 8 a.m. - 5 p.m. to assist you.

Enter your phone number below and we will connect you for free.

• Mission Statement
• Clinical Trials
• Aesthetic Trials

Open Enrollment

• Patient Resources
• Sponsor Resources
• Publications

(973) 509-2000

New Jersey Clinical Research Center

LEARN MORE ABOUT OUR MEDICAL DEVICE AND AESTHETIC FOCUSED TRIALS

The Research Center

Dr. Barry DiBernardo

Lead investigator.

Claudia Jennings

The Best Decision Of My Life

“I researched many doctors for over a five-year period and decided to go with Dr. DiBernardo who was rated one of the best plastic surgeons in the country. I got a tummy tuck and breast lift with implants and would love to post my picture. I finally have the body that I dreamed of!”

“Beautiful cohesiveness

“My confidence level in them all is 100%. They presented me with choices just for me even down to my compression garment - it was all for me! I loved my experience, I would definitely recommend Dr. DiBernardo & his staff!!”

Extremely professional and welcoming

“My son needed surgery and from the moment I knew that he needed a plastic surgeon, Dr. Dibernardo was the only person I would have trusted to perform surgery on my son. Thank you!”

Perfect surgeon for my breast lift.

“The moment I met Dr. DeBernardo I really really liked him. He was pleasant and informative. I felt like I was in good hands. He suggested I get a special suture that would enhance the lift and provide better fullness at the top of the breast.”

I could not be happier.

“From the first day, I looked 'down' after my surgery, to this very day, I am confident about myself, and every day I appreciate the results. I was cared for and respected every step of the way. Always a professional, beautiful facility, friendly, and willing to work at making my experience as comfortable and convenient as possible.”

NJPS is absolutely First Class

“Residing in Los Angeles, and being a National Aesthetic Consultant, I know first hand what separates the best from the Elites. NJPS is in a class by itself! 2 Thumbs Up!!”

Dr. DiBernardo solved a lifelong skin issue.

“We had been to all the top doctors in NYC and NJ with very little success. He took the time to research a plan and execute it based on the best that science could offer. I highly recommend New Jersey Plastic Surgery!”

MISSION STATEMENT

To analyze, validate and quantify existing and future Aesthetic Treatments or technologies thru clinical and laboratory research.

WHAT WE OFFER

Latest Technologies

Medical Excellence

Dedicated Staff

Medical Device Studies

Pharmaceutical Studies

30+ Years Experience

At New Jersey Clinical Research Center (NJCRC), we pay a lot of attention to our clinical trials and the way they are conducted. Our Procedural Facilities include:

• New Jersey Plastic Surgery (Treatment Rooms)
• Garden State Surgery (In Office Surgery)
• OSI Private Surgery Center
• Clara Maas Medical Center (Full-Service Hospital)
• University of Pittsburgh Research Laboratories
• Canfield Scientific: Custom Imaging Solutions

Contact us to schedule an appointment to discuss your clinical trial needs.

ACTIVELY ENROLLING:

Cellulite improvement.

Buttocks Enhancement

Loose neck skin, skincare study, facial skin enhancement.

(Wrinkles and Pigment)

Patient Trials

I would like to apply to participate in an active or upcoming clinical trial being conducted by NJCRC.

Researcher Enrollment

I would like to enroll a new treatment, device, or procedure for clinical trial with NJCRC.

Patient Trials Form

Researcher Enrollment Form

When it comes to your appearance, never settle for second best.

New Jersey Clinical Research Center 29 Park St, Montclair, NJ 07042

New Jersey Clinical Research Center (NJ-CRC) is a Montclair, New Jersey based business collaboration with TMC Group that aims to bring science and products to market and the medical community.

New Jersey Clinical Research Center® 29 Park St Montclair NJ 07042

Mon-Fri: 9am – 5pm

Sat-Sun: Closed

© 2024 New Jersey Clinical Research Center, Office of Dr. Barry DiBernardo All Rights Reserved   |   Privacy Policy   |   Accessibility

idealmedhealth

…creating a healthy world

List of 40 pharmaceutical companies in New Jersey

The growth of the pharmaceutical companies in New Jersey is driven by several factors, including a lower cost of living, strong research from area campuses, a long history of big pharma, and an accommodating state government.

Due to facility expansions, acquisitions, and research institution mergers, as well as an increase in companies moving or starting operations in the Garden State, New Jersey is seeing a surge in pharmaceutical activity.

The state is also known for being a center for new drug approvals. So far this year, 16 of the 27 new FDA-approved products have come from companies with a significant presence in New Jersey. In 2014, 40% of drugs approved by the FDA came from companies with a strong presence in the state.

More than 3,000 companies in the pharma, medtech, and life sciences industries are currently located in New Jersey. The number is likely to rise in the coming years.

Growth and development of the pharmaceutical companies in New Jersey

Geography also plays a significant role in the development of the pharmaceutical industry in New Jersey.

Camden, Princeton, and South Brunswick are close to Wall Street and the US Food and Drug Administration in New York City, as well as a two-hour train ride to Washington, D.C. The time zone also makes it possible to conduct business with agencies in both California and the United Kingdom on the same day, according to Hart.

Several companies, including Pozen and Celgene, have recently taken steps to establish a presence in New Jersey. Celgene was the unidentified buyer of Merck & Co.’s former 1 million-square-foot R&D facility in Summit, New Jersey.

The Garden State’s operating tax credit, which allows businesses to sell their net operating losses to the New Jersey Treasury, makes doing business in New Jersey popular.

Celgene, one of the state’s most well-known biotechs, used the program until it became profitable, which helped it stay in the state, according to local officials.

It’s no secret that businesses prefer lower tax rates, which is why some have sought to relocate their corporate headquarters overseas.

Traditional pharmaceutical companies have thus spent years attempting to: acquire smaller pharmaceutical firms in order to benefit from the latter’s discoveries and agile corporate size; pursue treating “rare diseases” (those affecting 200,000 or fewer patients globally) as a business strategy; and, more broadly, look to global markets with billions of potential patients.

Clinical trials for several iterations of the above scenario are set to begin soon at Advaxis, which is based in Princeton and employs approximately 100 people.

The products have already been designed and developed, and many of them have gone through manufacturing training.

Pharmaceutical companies in New Jersey

Here’s a comprehensive list of some of the pharmaceutical companies operating in New Jersey:

Actavis LLC

Address : 5 Giralda Farms Madison, NJ, 07940-1027 United States

Phone : (862) 261-7000

Website : Click Here

Sales : $1.45 billion

Year Started : 1985

Akorn New Jersey Inc

Address : 1925 West Field Court, Suite 300 | Lake Forest, IL 60045

Phone : 1-800-932-5676

Email : [email protected]

Allergan, Inc.

Sales : $2.63 billion

Year Started : 1977

Incorporated : 1977

Alvogen Group, Inc.

Address : 44 Whippany Rd Ste 300 Morristown, NJ, 07960-4558 United States

Phone : (973) 796-3400

Website : Click here

Sales : $568.17 million

Year Started: 2007

Incorporated : 2007

Amerigen Pharmaceuticals

Address : 9 Polito Ave #900, Lyndhurst, NJ 07071, United States

Phone : +1 732-993-9827

Amneal Pharmaceuticals, Inc.

Address : 400 Crossing Blvd FL 3 Bridgewater, NJ, 08807-2863 United States

Phone : (908) 947-3120

Sales : $1.63 billion

Year Started : 2002

Incorporated : 2017

Arxada America LLC

Address : 412 Mount Kemble Ave Ste 200S Morristown, NJ, 07960-6666 United States

Phone : (201) 316-9200

Sales : $1.83 billion

Year Started : 1980

Aspire Pharmaceuticals Inc

Phone : 732-447-1444

Address : 41 Veronica Ave, Somerset NJ, 08873

Aurobindo Pharma U.S.A., Inc.

Address : 279 Princeton Hightstown Rd East Windsor, NJ, 08520-1401 United States

Phone : (732) 839-9400

Sales: $1.43 billion

Year Started: 2003

Incorporated : 2004

BASF Corporation

Address : 100 Park Ave Florham Park, NJ, 07932-1089 United States

Phone : (800) 962-7831

Sales : $2.23 billion

Year Started : 1873

Barr Laboratories, Inc.

Address : 400 Interpace Pkwy Ste A1 Parsippany, NJ, 07054-1119 United States

Phone : (215) 591-3000

Sales : $1.44 billion

Year Started : 2003

Incorporated : 2003

Bausch Health Americas, Inc.

Address : 400 Somerset Corporate Blvd Bridgewater, NJ, 08807-2867 United States

Phone : (908) 927-1400

Sales : $2.82 billion

Year Started : 1994

Incorporated : 1994

Bayer Healthcare LLC

Address : 100 Bayer Blvd Whippany, NJ, 07981-1544 United States

Phone : (862) 404-3000

Sales : $1.70 billion

Year Started: 2002

Capsugel, Inc.

Address: 412 Mount Kemble Ave Ste 200C Morristown, NJ, 07960-6674 United States

Sales : $582.97 million

Year Started: 2011

Incorporated : 2011

Catalent, Inc.

Address : 14 Schoolhouse Rd Somerset, NJ, 08873-1213 United States

Phone : (732) 537-6200

Sales : $4.00 billion

Sales Growth : 29.22%

Year Started : 2007

Celgene Corporation

Address : 86 Morris Ave Summit, NJ, 07901-3915 United States

Phone : (908) 673-9000

Sales : $15.28 billion

Year Started : 1986

Incorporated: 1986

Church & Dwight Co., Inc.

Address : 500 Charles Ewing Blvd Ewing, NJ, 08628-3448 United States

Phone : (609) 806-1200

Sales : $5.19 billion

Sales Growth: 12.35%

Year Started : 1846

Incorporated : 1925

Chugai Pharma USA, Inc.

Address : 300 Connell Drive, Suite 3100 Berkeley Heights, NJ 07922

Phone : +1 908-516-1350

Glaxosmithkline Consumer Healthcare Holdings (us) LLC

Address : 184 Liberty Corner Rd Ste 200 Warren, NJ, 07059-6870 United States

Phone : (215) 751-5046

Sales : $569.44 million

Year Started : 2015

Hoffmann-La Roche Inc.

Address : 150 Clove Rd Ste 8 Little Falls, NJ, 07424-2139 United States

Phone : (973) 890-2268

Sales : $1.08 billion

Year Started : 1905

Incorporated : 1928

Integra Lifesciences Holdings Corporation

Address : 1100 Campus Rd Princeton, NJ, 08540-6650 United States

Phone : (609) 275-0500

Sales : $1.54 billion

Sales Growth : -9.6%

Year Started : 1989

Incorporated : 1989

Ingenus Pharmaceuticals NJ, LLC

Address : 140 New Dutch Lane Fairfield, New Jersey 07004

Phone : (862) 210-8536

Janssen Pharmaceuticals, Inc.

Address : 1125 Bear Tavern Rd Titusville, NJ, 08560-1499 United States

Phone : (609) 730-2000

Sales : $1.26 billion

Year Started : 1978

Johnson & Johnson

Address : 1 Johnson AND Johnson Plz New Brunswick, NJ, 08933-0002 United States

Phone : (732) 524-0400

Sales : $93.78 billion

Sales Growth : 0.64%

Year Started : 1886

Incorporated : 1887

Kedrion Biopharma Inc.

Address : 400 Kelby St Ste 11 Fort Lee, NJ, 07024-2938 United States

Phone : (201) 242-8900

Sales : $588.40 million

Year Started : 2011

Merck & Co., Inc.

Address : 2000 Galloping Hill Rd Kenilworth, NJ, 07033-1310 United States

Phone : (908) 740-4000

Sales : $48.70 billion

Sales Growth : 2.46%

Year Started : 1891

Incorporated : 1970

Mindray Ds Usa, Inc.

Address : 800 MacArthur Blvd Mahwah, NJ, 07430-2001 United States

Phone : (201) 995-8000

Sales : $572.42 million

Year Started: 2008

Novartis Corporation

Address : 1 S Ridgedale Ave Ste 122 East Hanover, NJ, 07936-3142 United States

Phone : (212) 307-1122

Sales : $49.67 billion

Year Started : 1903

Incorporated : 1966

Novo Nordisk Inc.

Address : 800 Scudders Mill Rd Plainsboro, NJ, 08536-1606 United States

Phone : (609) 987-5800

Sales : $8.00 billion

Year Started : 1982

Incorporated : 1982

Organon & Co.

Address : 30 Hudson St FL 17 Jersey City, NJ, 07302-4805 United States

Phone : (551) 430-6900

Sales : $578.58 million

Year Started: 2020

Ortho Clinical Diagnostics Holdings PLCs

Address : 1001 US Highway 202 Raritan, NJ, 08869-1424 United States

Phone : (908) 218-8000

Sales : $1.77 billion

Year Started : 2020

Phibro Animal Health Corporation

Address : 300 Frank W Burr Blvd Ste 21 Teaneck, NJ, 07666-6712 United States

Phone : (201) 329-7300

Sales : $833.35 million

Sales Growth : 4.12%

Year Started : 1946

Incorporated : 2014

Pts Intermediate Holdings LLC

Sales : $1.55 billion

Quest Diagnostics Incorporated

Address : 500 Plaza Dr Ste G Secaucus, NJ, 07094-3656 United States

Phone : (973) 520-2700

Sales : $10.79 billion

Sales Growth : 22.15%

Year Started: 1967

Incorporated : 1990

Sandoz Inc.

Address : 100 College Rd W Princeton, NJ, 08540-6604 United States

Phone : (609) 627-8500

Sales : $709.04 million

Year Started: 1963

Incorporated : 1975

Sanofi-Synthelabo LLC

Address : 55 Corporate Dr Bridgewater, NJ, 08807-1265 United States

Phone : (908) 981-5000

Sales : $2.05 billion

Year Started: 1989

Sun Pharmaceutical Industries, Inc.

Address : 2 Independence Way Princeton, NJ, 08540-6620 United States

Phone : (609) 495-2800

Sales : $800.00 million

Year Started : 1984

Incorporated : 1984

Teva Pharmaceuticals Usa, Inc.

Website : visit

Sales : $2.89 billion

Year Started: 1985

Vitamin Shoppe Industries LLC

Address : 300 Harmon Meadow Blvd Ste 505 Secaucus, NJ, 07094-3638 United States

Phone : (201) 552-6000

Sales : $641.64 million

Zoetis Inc.

Address : 10 Sylvan Way Ste 105 Parsippany, NJ, 07054-3825 United States

Phone : (973) 822-7000

Sales : $6.67 billion

Sales Growth : 6.63%

Year Started : 1952

Incorporated : 2012

FAQs about the pharmaceutical companies in New Jersey

• What pharmaceutical companies are the top players in New Jersey?

Johnson & Johnson headquartered in New Brunswick, NJ. Known as Merck in the United States and Canada, the company is known as MSD in the rest of the world, Bristol-Myers Squibb, Novartis, Celgene, Bayer HealthCare, Sanofi, Stryker Orthopedics are some of the top players in New Jersey.

• How many pharmaceutical firms are there in New Jersey?

In 2014, 40% of drugs approved by the FDA came from companies with a strong presence in the state. More than 3,000 companies in the pharma, medtech, and life sciences industries are currently located in New Jersey.

• Is Pfizer headquartered in New Jersey?

Pfizer Inc. is a pharmaceutical and medicine manufacturing company headquartered in Warren, New Jersey, United States.

• How many biotech companies are there in New Jersey?

And, whereas New Jersey had only 30 biotechnology firms in 1994, the state now has over 350 such firms, a result that not only reflects New Jersey’s “Medicine Chest of the World” history but also reveals a rapidly advancing scientific community that has sequenced the human genome and can sequence the human genome.

New Jersey has a long history of developing life-saving medicine, dating back over a century. New Jersey has it all for life sciences companies: research, talent, funding, available space, university partnerships, and industry expertise.

The city is home to 14 of the top 20 pharmaceutical companies. Several industry leaders, including Celgene (a pioneer in oncology, acquired by Bristol-Myers Squibb for $74 billion in 2019) and Amicus Therapeutics, have found success here (which received its first FDA approval for rare diseases in 2018).

New Jersey has the highest density of scientists and engineers per square mile in the United States, as well as over 3,200 life sciences companies operating in all sectors. New Jersey is the only state that has a concentration in four of the five bioscience subsectors.

Recommendations

• Top pharmaceutical companies in Texas
• List of 40 pharmaceutical companies in South Korea
• Best pharmaceutical companies in Indonesia
• List of pharmaceutical companies in Ukraine 
• Top pharmaceutical companies in the UK

Chibueze Uchegbu is a certified medical physiologist with a great passion for healthy living.

One comment

• Pingback: Top 40 pharmaceutical companies in Maryland - idealmedhealth

Leave a Reply Cancel reply

You must be logged in to post a comment.

Privacy Overview

Find the right market research agencies, suppliers, platforms, and facilities by exploring the services and solutions that best match your needs

list of top MR Specialties

Browse all specialties

Browse Companies and Platforms

by Specialty

by Location

Browse Focus Group Facilities

Manage your listing

Follow a step-by-step guide with online chat support to create or manage your listing.

About Greenbook Directory

IIEX Conferences

Discover the future of insights at the Insight Innovation Exchange (IIEX) event closest to you

IIEX Virtual Events

Explore important trends, best practices, and innovative use cases without leaving your desk

Insights Tech Showcase

See the latest research tech in action during curated interactive demos from top vendors

Stay updated on what’s new in insights and learn about solutions to the challenges you face

Greenbook Future list

An esteemed awards program that supports and encourages the voices of emerging leaders in the insight community.

Insight Innovation Competition

Submit your innovation that could impact the insights and market research industry for the better.

Find your next position in the world's largest database of market research and data analytics jobs.

For Suppliers

Directory: Renew your listing

Directory: Create a listing

Event sponsorship

Get Recommended Program

Digital Ads

Content marketing

Ads in Reports

Podcasts sponsorship

Run your Webinar

Host a Tech Showcase

Future List Partnership

All services

Dana Stanley

Greenbook’s Chief Revenue Officer

Top Marketing Research Firms in New Jersey

Featured marketing research firms in new jersey.

in New Jersey

Service or Speciality

Advanced Analytics

Advertising Agencies

Advertising Effectiveness

Advertising Research - General

Advertising Tracking

African-American

Alcoholic Beverages

Artificial Intelligence / AI-Powered Platforms

Attitude & Usage Research

Automated Speech Transcription

B2B Research - General

Brainstorming / Facilitation

Brand / product / service launch

Brand / product / service repositioning

Brand Equity

Brand Identity

Brand Image Tracking

Brand Loyalty / Satisfaction

Brand Positioning

Bulletin Boards

Business Insights

Business-to-Business

CAPI - Computer-Aided Personal Interviewing

CATI - Computer-Aided Telephone Interviewing

CX - Customer Experience

Cannabis / CBD

Central Location

Claims Substantiation

Communications Strategy Research

Concept Development

Concept Optimization

Concept Testing

Concept Testing - Advertising

Conjoint Analysis / Trade-off/Choice Modeling

Construction Industry

Consultation

Consumer Durables

Consumer Research - General

Consumer Trends

Controlled Store Tests

Copy Testing - Traditional Media

Crowdsourcing & Co-creation

Customer Satisfaction

DIY Surveys (do-it-yourself)

Data Processing

Data Tabulation

Distribution Checks

Doctors / Physicians

East Asia & China

Emotional Measurement

Entertainment Industry

Environment & Sustainability

Ethnography / Observational Research

Executives / Professionals

Exit Interviews

Eye Tracking

Facial Coding & Analysis

Field Audits

Field Services

Financial Industry

Focus Group Facility

Focus Group Recruiting

Focus Groups

Focus Groups - International

Focus Groups - Pop-Up

Foods / Nutrition

Forecasting & Predictive Analytics

Fragrance Industry

Full Service

Gamification / Research Games

General - Healthcare

Generation Z

Global Capabilities

High Net Worth

High Technology

Hispanic / Latino

Home Use Tests

Household Products/Services

Hybrid / Mixed Methodology

Idea Generation

Implicit Association

In-Depth / One-on-One

Industrial & Manufacturing

International / Multi-country

International Consumer Market Research

Journey Mapping

Lifestyle & Value Trends

Mall Intercept

Market & Competitive Intelligence

Market Segmentation

Market Simulation

Media Market Research

Medical / Health Care

Merchandising Audits

Mobile Ethnography

Mobile Qualitative

Mobile Surveys

Mock Juries

Moderator Services

Multi-Country Studies

Mystery Shopping

NPS Measurement

Naming Research / Name Development

Neuromarketing

New Products

Non-Profit / Fund Raising

Nurses / Nurse Practitioners

Omnibus Surveys

One-on-One / In-depth Interviews (IDIs)

Online - Quantitative

Online Communities - MROC

Online Diaries / Journals / Blogs

Online Focus Group Platforms & Software

Online Panels

Online and Mobile Platforms

Open-End / Verbatim Response Coding

Packaged Goods

Packaging Testing

Personal Care Items

Pet Owners / Foods / Supplies

Pharmaceutical - OTC Medicines

Pharmaceutical - Prescription Medicines

Political Polling

Pre-Recruiting

Price / Pricing

Price Elasticity

Product Development

Product Market Research

Product Optimization

Product Purchasing / Sample Pick-up

Product Testing

Proprietary Panels

Psychological / Motivational Research

Purchase Behavior

Qualitative Research

Qualitative Services - General

Quantitative Research

Questionnaire / Survey Design

Questionnaire Coding

Recruiting Research

Retail Industry

Segmentation

Seniors / Mature

Sensory Research

Shopper Insights

Small Business / Startups / Entrepreneurs

Social, political, non-profit goals

Store Audits

Strategic Research

Supermarkets & Grocery Stores

Surgical Products / Medical Devices

Survey Programming

Survey Reporting and Analysis

Syndicated / Published Reports

Taste Test Facility

Taste Tests / Sensory Tests

Telecommunications

Test Marketing

Test/Commercial Kitchen

Transcription Services

Translation Services

Usability Lab

User Testing

Utilities / Energy

Video Management Platforms

Web Broadcasting / Streaming Video

New York (NY--NJ--CT)

Orlando (FL)

Philadelphia (PA--NJ--DE--MD)

Vendor type

Data & Analytics

Data Collection

International

Panels / Communities

Qualitative Consultant

Software & Technology

Support Services

Business Designation

HIPAA Compliant

SBE Certified

Veteran-Owned Business

Women-Owned Business

Clear filters ( 0 )

Compare New Jersey

Ridgewood, New Jersey

SOCIAL MEDIA

Save to my lists

Featured expert

Provoke Insights

A full service international market research firm that specializes in branding, advertising, & content marketing initiatives in the B2C & B2B space.

Why choose Provoke Insights

Brand & Media Strategists

Researchers + Strategy

Cross-discipline Approach

Nothing Outsourced

Trend Spotters

Learn more about Provoke Insights

Cranford, New Jersey

CEC Research

Consumer Evaluation Center located in Central NJ provides superior facilities and recruiting for all of your Sensory and Consumer Research needs.

Why choose CEC Research

Commercial Kitchen

Fragrance & Flavor Tests

Laundry Facilities

Learn more about CEC Research

Fort Lee, New Jersey

Fieldwork Fort Lee, NJ

5 research suites with viewing designed for maximum client comfort. Local database, recruiting and project management.

Why choose Fieldwork Fort Lee, NJ

5 Flexible Rooms

On-Site Recruiting

Experienced Staff

Great Location

Learn more about Fieldwork Fort Lee, NJ

Iselin, New Jersey

Sago New Jersey

Sago is a leading global research partner that puts the human voice at the center of everything we do.

Why choose Sago New Jersey

Global Respondent Access

Collaborative Approach

Programmatic Surveys

Digital Qual Platforms

World-Class Facilities

Learn more about Sago New Jersey

Ormond Beach, Florida

CRG Global - Test America (Branch)

CRG Global specalizes in full service market research including CLTs, HUTs, focus groups, mobile research, eye tracking, facial coding, and more.

Why choose CRG Global - Test America (Branch)

40 + yrs in the Industry

Executional Expertise

Global Data Collection

Purpose-built Facilities

Extensive Panel 440K+

Learn more about CRG Global - Test America (Branch)

Red Bank, New Jersey

KLC delivers always on human insight. Our custom insights communities help companies build better experiences, better marketing, & better products

Why choose KLC

Experience and Expertise

90+ % Client Retention

Always On Solution

Incredible Value

Learn more about KLC

Hauser & Associates, Inc.

Hauser & Associates helps research professionals meet their constant deadlines by offering more research in less time. Results on time, every time.

Why choose Hauser & Associates, Inc.

Agile to Meet Your Needs

Quick Turnaround

Experienced Researchers

Reliable Partner

Actionable Results

Learn more about Hauser & Associates, Inc.

Cherry Hill, New Jersey

MAXimum Research

We are telephone interviewing specialists with over 300 CATI stations running the Survox (formerly CfMC) Interviewing & Internet Package w/ Hosting.

Why choose MAXimum Research

Competitive Pricing

Best Customer Service

All Industries

High Quality/Reliability

Extensive Experience

Learn more about MAXimum Research

Hoboken, New Jersey

SKIM is a global insights agency helping leading companies thrive by understanding decision making.

Why choose SKIM

Price&Portfolio Strategy

Decision Journey Mapping

Decades of Comm Research

Conjoint Analysis

Learn more about SKIM

East Rutherford, New Jersey

Focus Crossroads - East Rutherford, NJ

Focus Crossroads, recruitment experts and one of Northern NJ's top-rated qualitative facilities, conveniently located in the NYC Metro Area.

Why choose Focus Crossroads - East Rutherford, NJ

B2B recruitment experts

Conveniently-located

Access diverse consumers

Top-rated facility

Recruits healthcare pros

Learn more about Focus Crossroads - East Rutherford, NJ

Fairfield, New Jersey

Capstone Research, Inc.

Capstone provides a full range of services across all aspects of market research, with particular expertise in on-premise retail research.

Why choose Capstone Research, Inc.

#1 in Data Collection

Decades of Experience

Thousands of Auditors

Coverage Across USA

Learn more about Capstone Research, Inc.

Mount Laurel, New Jersey

aytm’s automated platform empowers you to gain powerful insights, explore a deeper understanding of your consumer, and evolve your ideas in real-time.

Why choose aytm

Well-nurtured respondents

Expert-automated tools

Robust insights platform

Future-focused enablement

Flexible research service

Learn more about aytm

Glen Rock, New Jersey

Bauman Research & Consulting, LLC

Full-service market research & consulting firm, qualitative & quantitative, specializing in branding, positioning, concept testing, expert moderator

Why choose Bauman Research & Consulting, LLC

Decades of experience

Senior people do the work

Client service oriented

We make your job easier

We love helping clients

Learn more about Bauman Research & Consulting, LLC

Newark, New Jersey

APLUSA's US division is a full-service firm with core strengths in segmentation, demand forecasting, chart data innovations, and hybrid qualitative

Why choose APLUSA

Real-world data

Global presence

Oncology expertise

Demand forecasting

Learn more about APLUSA

Summit, New Jersey

BEESY is a top-rated insights agency applying rigorous behavioral science solutions to unlock competitive opportunities and advance commercial outcome

Why choose BEESY

Commercial Outcomes

Market More Effectively

Behavioral Science Expert

Identify Behavior Barrier

Impact Decision Making

Learn more about BEESY

Sign Up for Updates

Get the latest updates from top market research, insights, and analytics experts delivered weekly to your inbox

I agree to receive emails with insights-related content from Greenbook. I understand that I can manage my email preferences or unsubscribe at any time and that Greenbook protects my privacy under the General Data Protection Regulation.*

Your guide for all things market research and consumer insights

Create a New Listing

Manage My Listing

Find Companies

Find Focus Group Facilities

Tech Showcases

GRIT Report

Expert Channels

Get in touch

Marketing Services

Future List

Publish With Us

Privacy policy

Cookie policy

Terms of use

Copyright © 2024 New York AMA Communication Services, Inc. All rights reserved. 234 5th Avenue, 2nd Floor, New York, NY 10001 | Phone: (212) 849-2752